WO2001007009A1 - Lysine oxidase linkage of agents to tissue - Google Patents
Lysine oxidase linkage of agents to tissue Download PDFInfo
- Publication number
- WO2001007009A1 WO2001007009A1 PCT/US2000/020211 US0020211W WO0107009A1 WO 2001007009 A1 WO2001007009 A1 WO 2001007009A1 US 0020211 W US0020211 W US 0020211W WO 0107009 A1 WO0107009 A1 WO 0107009A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- lysine
- lysine oxidase
- linker
- reactive groups
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8105—Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers
- A61K8/8117—Homopolymers or copolymers of aromatic olefines, e.g. polystyrene; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/86—Products or compounds obtained by genetic engineering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/94—Involves covalent bonding to the substrate
Definitions
- This invention relates to the linkage of agents to tissue by lysine oxidase and involves methods, products and kits relating thereto.
- Transglutaminases are a family of calcium-dependent enzymes mediating covalent crosslinking reactions between specific peptide bound ⁇ -glutamyl residues and various primary amino groups of peptide-bound lysines or polyamines, acting as amine donor substrates (Davies, et al., Adv. Exp. Med. Biol. 250, 391-401, 1988). These enzymes stabilize biological structures via the formation of isopeptide crosslinks. In mammals, at least five enzymatically active transglutaminases have been identified, cloned and sequenced. The number of proteins acting as glutaminyl substrates for transglutaminases is restricted, and no obvious consensus sequence around these substrates' glutamines has been found.
- transglutaminases and corneocyte proteins can be used together as cosmetic treatments to crosslink preparations of corneocyte proteins to the outer layer of skin, hair or nails to form a protective layer on the skin, hair or nails.
- U.S. Patent 5,490,980 describes selecting agents having or modifying agents to have an aliphatic amine, and then attaching those agents to skin, hair or nails using transglutaminase. While the idea was sound in principle, in practice the '980 applicants achieved results that were barely above background. (See Example Section of '980 patent). An aliphatic amine was applied in the examples as a single linking molecule or prophetically in clusters (according to a formula in the '980 patent).
- Lysine oxidase (EC 1.4.3.14) catalyzes the oxidative transformation of the ⁇ -amino group of lysine to an aldehyde group. The resultant aldehyde group in turn undergoes an intermolecular Schiff base formation with amino groups of proteins or an aldol condensation with other aldehyde groups to forge cross links.
- Lysine oxidase (CAS # 70132-14-8;) is commercially available from Sigma Chemical Co., St. Louis, MO) (Cat. # L6150), and United States Biochemical Company (Cat. # 18612). Summary of The Invention
- lysine oxidase e.g., lysines
- agents including microparticles containing agents
- Lysine oxidase reacts with lysine amines to form aldehydes (i.e., lysyl aldehydes).
- lysyl aldehydes formed from lysyl amines by lysine oxidase are referred to as "lysine oxidase products" or “products of lysine oxidase.”
- molecules, including native peptides and conjugates according to the invention can be screened to determine those that can be substrates of lysine oxidases and those that can react with products of lysine oxidase, and then such molecules can be attached to a body tissue. Methods of attaching agents to body tissue and methods of screening molecules that are useful in such a process using lysine oxidase are provided.
- compositions of matter suitable as substrates for lysine oxidase, or which can react with lysine oxidase products such as aldehydes, and kits containing such molecules together with lysine oxidase are also provided.
- a method for attaching an agent to a body tissue An agent attached to a linker that is selected from the group consisting of compounds that are substrates of lysine oxidase (i.e., it possesses a lysine residue) and compounds that react with lysine oxidase products (i.e., it possesses an aldehyde or amine),k and the conjugate of the agent and linker is applied to the body tissue.
- lysine oxidase also is applied to the body tissue, in an amount effective to permit crosslinking the agent which is attached to the linker to the body tissue. Thus attachment of the agent to the tissue occurs via the linker. Crosslinking then is allowed to occur.
- an effective amount of lysine oxidase can be defined in terms of production of lysine oxidase products (e.g., aldehydes from lysine amines) or in terms of crosslinking of such products to their counterpart reactive molecules (e.g., amines and other aldehydes).
- the lysine oxidase is applied to the body tissue first.
- the linker comprises a lysine oxidase substrate preferably in the form of a lysine residue.
- the lysine oxidase acts on the linker and the linker can then react with an amine in the tissue.
- the lysine oxidase also could act on the body tissue and the linker to generate aldehydes on both. These aldehydes are then able to react spontaneously with each other.
- the linker comprises a reactive moiety that reacts with lysine oxidase products (i.e., it reacts with aldehydes). Such moieties are preferably amines or aldehydes.
- the linker may comprise a molecule selected from the group consisting of at least one amine, aldehyde or lysine, at least two contiguous linked amines, aldehydes or lysines, at least three contiguous linked amines, aldehydes or lysines, at least four contiguous linked amines, aldehydes or lysines, or at least five contiguous linked amines, aldehydes or lysines.
- the linker comprises 4 or more contiguous amines, aldehydes or lysines attached directly to one another by covalent bonds, such as peptide bonds.
- the linker comprises a polymer.
- the polymer may be a polymer of amino acids. In some embodiments, at least 20%, at least 30%, or at least 40% or more of the amino acids are lysines.
- the method further comprises first treating the body tissue to expose reactive molecules in the tissue (such as lysines).
- the method further comprises first attaching to the body tissue a complementary linker, and attaching the complementary linker and the agent to one another by crosslinking the linker (which is attached to the agent) and the complementary linker by the lysine oxidase.
- the crosslinking occurs after exposure to lysine oxidase.
- the complementary linker is attached to the body tissue by applying to the body tissue the complementary linker, applying to the body tissue an amount of lysine oxidase effective for crosslinking the complementary linker to the body tissue, and allowing said crosslinking to occur.
- the linker or complementary linker comprise a polymer rich in lysine.
- the polymer rich in lysine has 4 or more contiguous lysines directly attached to one another by peptide bonds.
- the complementary linker may be crosslinked to the body tissue using transglutaminase, in some embodiments.
- the agent itself may, or may not, be a substrate of lysine oxidase.
- the agent may be, or may not be, capable of spontaneously reacting with a lysyl aldehyde.
- the agent does not itself react with lysine oxidase substrates.
- the body tissue may be integument, skin, hair, nails, a wound bed, and/or internal body tissue.
- the agent may be a cosmetic, a bulking agent, a sunscreen agent, and/or a coloring agent.
- the agent may be an enzyme.
- the enzyme includes a cholinesterase and/or a phosphodiesterase.
- the agent is an anti-nerve agent.
- the agent is an enzyme which degrades nerve agents and may be selected from the group consisting of OPAA anhydrolase and squid type OPA anhydrase.
- the agent may be a pharmaceutical agent, a ligand of a ligand-receptor complex, and/or a receptor of a ligand-receptor complex.
- the bond between the agent and the linker is a hydrolyzable bond.
- the agent may be a nonprotein.
- the agent and/or linker are provided as a microparticle. In other embodiments, the agent and/or linker are not provided as part of a microparticle.
- the invention provides a method for attaching an agent to a body tissue comprising first attaching to the body tissue a linker which is covalently bondable to the agent in the presence of lysine oxidase, then applying to the body tissue having the linker attached thereto an agent which is covalently bonded to the linker in the presence of lysine oxidase, applying to the body tissue lysine oxidase in an amount effective to crosslink that agent to the linker and allowing the crosslinking to occur.
- the linker is a substrate of lysine oxidase and the linker is attached to the body tissue by applying to the body tissue the linker, applying to the body tissue the lysine oxidase in an amount effective to crosslink the linker to the body tissue and allowing the crosslinking to occur.
- the a polymer rich in lysine is the linker.
- the agent comprises a polymer rich in lysine. In one embodiment the agent does not comprise a microparticle, and in another the linker does not comprise a microparticle.
- the agent may be any of the agents described herein including an enzyme that degrades nerve agents such as OPPAA anhydrolase or squid type OPA anhydrase.
- a method for attaching an agent to a body tissue.
- the method involves selecting an agent that is a substrate for lysine oxidase or an agent that can react (spontaneously) with a lysine oxidase product (i.e., a lysyl aldehyde).
- the agent in an isolated form, then is applied to the body tissue in the presence of a sufficient amount of lysine oxidase to crosslink the isolated agent to the body tissue.
- this amount embraces the amount sufficient for converting lysyl amines (lysine oxidase substrates) to lysyl aldehydes (lysine oxidase products).
- crosslinking then is allowed to occur.
- the crosslinking in all embodiments of the invention may occur in the absence or the presence of lysine oxidase, provided a sufficient number of lysine oxidase products have been produced prior to the crosslinking.
- the agent can be attached to a linker, and the linker may not be native to the agent. It also is the case that the agent can be a native agent free of attachment with linkers (or molecules) not native to the agent.
- the agent and/or linker are provided as a microparticle. In other embodiments, the agent and/or linker are not provided as part of a microparticle.
- the linker can be any number of a variety of linkers.
- the linker is at least one amine or aldehyde.
- the linker likewise, may comprise two or more contiguous linked amines or aldehydes.
- the linker is a polymer.
- the polymer may be rich units having amines or aldehydes.
- a polymer rich in amines or aldehydes is a polymer with at least 20% of units having amines or aldehydes or it is a polymer having at least three, preferably four and most preferably five contiguous, linked units comprising amines or aldehydes, preferably linked by peptide bonds.
- the polymer rich in units having amines or aldehydes can be a polymer that contains at least 30%, at least 40%, or even 50% or more of such units.
- a transglutaminase may also be used as well as the lysine oxidase according to the invention.
- lysine groups are first prepared for crosslinking through exposure to lysine oxidase which converts amines to aldehydes.
- the methods described above involve first preparing the body tissue for the attachment of the agent to the body tissue.
- a complementary linker that is attachable to the linker by lysine oxidase or otherwise is first attached to the body tissue to provide multiple, accessible linking sites for the attachment of the linker to the body tissue.
- the complementary linker can be attached to the body tissue by any suitable means, but preferably is attached by applying the complementary linker to the body tissue, and applying lysine oxidase or transglutaminase to the body tissue in an amount effective for crosslinking the complementary linker to the body tissue. Crosslinking then is allowed to occur.
- the complementary linker is a polymer rich in lysine, or both glutamine and lysine.
- attachment or crosslinking by lysine oxidase embraces the reaction of lysines with lysine oxidase (to form aldehydes) followed by the spontaneous reaction of so generated aldehydes with other aldehydes (i.e., an aldol condensation reaction) or with amine groups such as those of lysine (i.e., a Schiff base formation) to form crosslinks.
- polylysine could first be attached to the surface of a body tissue using lysine oxidase. Subsequently polylysine could be attached to the polylysine by lysine oxidase, and so forth, to create layers of such molecules in the body tissues, for example, for bulking purposes or to provide an even, continuous bed of reactive groups for linking an active agent to the body tissue. Transglutaminase could be used for this purpose as well.
- a pair of molecules which are covalently joined are said to be "complementary" molecules.
- polymers comprising polylysine may first be attached to a body tissue. Then, agents attached to polylysine may be applied to the coated body surface and easily attached to the exposed lysines of the polylysines on the body surface. Similarly, agents attached to linkers containing aldehyde groups, or agents which themselves have aldehyde groups, may be applied to the coated body surface and easily attached to the exposed lysines of the polylysines on the body surface.
- the exposed lysines may be treated with lysine oxidase before, during or after exposure to the agents.
- the body surface or the linker is pretreated with lysine oxidase.
- the agent (or native agent) is not itself a substrate of lysine oxidase nor can it react with lysine oxidase products (i.e., it does not contain lysine or amines or aldehydes).
- the agent be attached to a compound that is a substrate of lysine oxidase or to a molecule that can spontaneously react with lysine oxidase products whereby the agent may be attached to the body tissue by such compounds which provide the linker.
- the compound may comprise aliphatic amines which can be oxidized by lysine oxidase and then coupled to amines or aldehydes, or alternatively, it may itself contain amines and aldehydes and thus can couple to aldehydes generated by the action of lysine oxidase. It also is possible to modify peptide agents by adding a side group, whereby the agent which itself is not a substrate of lysine oxidase is converted to a substrate of lysine oxidase.
- the agents, and agents attached to linkers are attached to proteinaceous material.
- the preferred proteinaceous material is body tissue, including the integument, a wound bed, internal organs or internal tissue. Even more preferred in some embodiments are the skin, nails and hair.
- the agent can be any variety of agents, including cosmetics such as bulking agents, coloring agents, sunscreen agents, hair conditioning agents, hair fixative agents, anti-foaming agents, moisturizing agents, including humectants, and depilatories (i.e., hair removal agents), vitamins, film forming agents such as those used in hair fixatives or wound healing, insect repellants including louse repellents, anti-nerve gas or anti-neurotoxin agents such as enzymes including cholinesterase and phosphodiesterase, pharmaceutical agents, ligands of ligand-receptor complexes, receptors of ligand-receptor complexes, and the like.
- cosmetics such as bulking agents, coloring agents, sunscreen agents, hair conditioning agents, hair fixative agents, anti-foaming agents, moisturizing agents, including humectants, and depilatories (i.e., hair removal agents)
- vitamins film forming agents such as those used in hair fixatives or wound healing
- the agent is an enzyme that degrades nerve agents and may be selected from the group consisting of OPAA anhydrolase and squid type OPA anhydrase.
- the agent is a member of a noncovalent coupling pair, such as biotin and avidin, to provide a universal linker as discussed in greater detail below.
- the bond between the agent and the linking molecule can be a bond which cleaves under normal physiological conditions or which can be caused to cleave specifically, for example, by exposure to light.
- the agent is not itself a substrate of lysine oxidase, the agent is a non-protein.
- a method for attaching an agent to a body tissue.
- a linker which is covalently bondable to the agent by any means including the use of lysine oxidase is attached to the body tissue.
- an agent is applied to the body tissue.
- Lysine oxidase also is applied to the body tissue, in an amount effective to crosslink the agent to the linking molecule. Crosslinking then is allowed to occur.
- the linker can be attached to the body tissue by any suitable means, but in one embodiment the linker is a substrate of lysine oxidase or transglutaminase and preferably it is attached to the body tissue by applying the linker to the body tissue together with lysine oxidase or transglutaminase, the lysine oxidase or transglutaminase being present in an amount effective to crosslink the linker to the body tissue.
- Preferred linkers are lysine and polymers of glutamine and/or lysine. Most preferred are polymers that are rich in lysine, or both glutamine and lysine.
- the agent can be any substance including those listed above but also including labels, extracellular matrix proteins and corneocyte proteins. Preferred body tissues are as described above. In some embodiments, the agent, linker or conjugate does not comprise a microparticle.
- a method for attaching an agent to a body tissue.
- the method involves first attaching to the body tissue a linker which is covalently bondable to the agent in the presence of lysine oxidase. Then, the method involves applying to the body tissue having the linker attached thereto an agent that is covalently bonded to the linker, in the presence of the sufficient amount of lysine oxidase effective to crosslink the agent to the linker attached to the body tissue. Crosslinking then is allowed to occur.
- Preferred agents, linkers and body tissues are as described above.
- a method for determining whether an agent is a substrate for lysine oxidase or whether it reacts with a lysine oxidase product.
- the method involves applying the agent in an isolated form to a proteinaceous material such as a body tissue, a body tissue isolate, a polymer rich in amine, such as preferably lysine and the like. Lysine oxidase then is applied to the proteinaceous material in an amount sufficient and under conditions appropriate to crosslink the agent to the proteinaceous material if the agent is a substrate of lysine oxidase or if it reacts with a lysine oxidase product.
- the agent covalently binds to the proteinaceous material, covalent binding being indicative that the agent is a substrate of lysine oxidase or if it reacts with a lysine oxidase product.
- the agent is an active agent and, in other preferred embodiments, the active agent is a covalent conjugate of a native active agent and a linker not native to the active agent. In other embodiments, the active agent is a native active agent free of conjugation with groups not native to the active agent.
- methods are provided for creating conjugates of active agents and linkers (or linking molecules) and determining whether the conjugates are substrates for lysine oxidase or whether they react with a lysine oxidase product.
- active agents such as pharmaceutical agents, cosmetics, sunscreen agents and the like, which are peptides in their native form, are screened to determine whether they are substrates of lysine oxidase or whether they react with a lysine oxidase product so that they may be attached to body tissue according to the invention.
- the proteinaceous material (including lysines) is exposed to lysine oxidase, after which the agent (or linker) is applied to the material. It is then determined whether the agent (or linker) is covalently attached to the material.
- the agent or linker may be applied to a solid support, lysine oxidase may be applied to the solid support coated with the agent or linker and a detectable label known to have amine, or more preferably, aldehyde groups, is applied to the support. If the detectable label remains attached to the support following washing, then this indicates a covalent bond and that the agent or linker was a substrate for lysine oxidase.
- a method for attaching an agent to a body tissue involves applying to the body tissue a conjugate of the agent and a linker which is an amine, an aliphatic amine or an aldehyde (preferably the linker being a polymer with at least 3 amines, aliphatic amines or aldehydes spaced along the polymer) applying to the body lysine oxidase in an amount effective for crosslinking the linker to the body tissue, and allowing crosslinking to occur.
- the amines and aliphatic amines can be the side chain of L or D lysines. D lysines have the advantage of being physiologically more stable than L lysines.
- the linker may include at least 3, at least 4 and at least 5 contiguous amines, aliphatic amines, lysines or aldehydes attached to one another directly by peptide bonds.
- the polymer also can be one rich in amines, aliphatic amines, or aldehydes.
- An example is a polymer rich in lysines, as described above.
- Preferred agents and body tissues are as described above.
- compositions of matter include conjugates of an agent and a linker, the linker in some embodiments being a substrate of lysine oxidase, in other embodiments being able to react spontaneously with a lysine oxidase product, and in still other embodiments, not being a substrate of transglutaminase.
- the agent includes a sunscreen agent, a bulking agent, a cosmetic, a hair conditioning agent including an anti-foaming agent or an anti-static agent, a hair fixative agent, a moisturizing agent, including a humectant, and a depilatory agent (i.e., a hair removal agent), a vitamin, a film forming agent such as those used in hair fixatives or wound healing, an enzyme, a coloring agent, a pharmaceutical agent, a member of a ligand/receptor pair, a component of a high-affinity non-covalent coupling pair, a tissue sealant, an insecticide including louse repellents, an insect repellant, a bactericide, a fungicide, an anti-nerve gas or anti-neurotoxin agent and the like.
- the linker is a substrate for lysine oxidase, is not a substrate of transglutaminase, and is not native to the agent.
- the linker contains amines or aldehydes and thus can spontaneously react with lysine oxidase treated tissue.
- the bond between the agent and the linker or molecule is a hydrolyzable bond.
- the agent is a non- protein.
- the agent is an active agent.
- the agent, in its native form free of conjugation to the linker is not itself a substrate of lysine oxidase.
- kits are provided.
- One such kit includes a package housing a first container containing an agent attachable to proteinaceous material in the presence of lysine oxidase and a second container containing lysine oxidase.
- the kit can further comprise a third container housed by the package, the third container containing a linker that is a substrate of lysine oxidase and that is covalently bondable to the agent contained in the first container in the presence of lysine oxidase.
- the various containers also can contain catalysts, vehicles, calcium, preservatives, buffers, and calcium chelators.
- the invention provides a kit comprising a microparticle comprising surface available reactive groups in an amount sufficient to attach the microparticle to a skin surface in the presence of lysine oxidase, and lysine oxidase.
- the kit further includes in one embodiment, instructions for topically administering the microparticles to a skin surface.
- the kit include a complementary linker.
- the surface available groups may be selected from the group consisting of amines, aldehydes, aliphatic amines, lysine and, in general, substrates of lysine oxidase.
- Other embodiments that pertain to microparticle compositions as described herein are also embraced.
- the invention provides a kit comprising a microparticle having surface available reactive groups in an amount sufficient to attach the microparticle to a skin surface in the presence of lysine oxidase, and instructions for topically administering the microparticle to a skin surface, wherein the surface available reactive groups are selected from the groups consisting of aldehydes and amines.
- the kit further comprising exogenous lysine oxidase.
- the kit further comprises a cleanser.
- it comprises a complementary linker.
- -l ithe microparticle is provided in a topically administered form selected from the group consisting of an ointment, an aerosol, a gel, and a lotion.
- the tissue can be pretreated to make it more receptive to the action of lysine oxidase. In one embodiment described above, this is accomplished by attaching polymers rich in lysine, or both glutamine and lysine to the body tissue. In other embodiments, the tissue is treated to expose reactive groups by washing, chemical treatment, etc. Detergents and Upases can be used to remove fatty acids and oils. Roughening agents such as pumice, silica and sandpaper can be employed to remove dead tissue and other obstructions, and chemical agents such as sodium hydroxide can be used to expose reactive groups. Combinations of the foregoing are contemplated. The tissue may also be pretreated by exposure to lysine oxidase.
- the invention also involves the use of lysine oxidase to 'glue' two tissues together.
- Two tissues are held in contact with one another in the presence of an effective amount of lysine oxidase, whereby the lysine oxidase causes the crosslinking of the tissue to occur by, for example, converting lysines on both surfaces to reactive aldehydes which can crosslink with each other spontaneously to seal the tissue.
- the surfaces of the tissues to be glued to one another may be treated with a substrate of lysine oxidase such as polymers rich in lysine to create highly reactive surfaces in the presence of lysine oxidase. These highly reactive surfaces are bonded to one another.
- the surfaces of the tissue are first treated with a primary linker to crosslink the primary linker to the surfaces, then a secondary linker complementary to the first is applied to crosslink the primary molecules to one another and glue the tissue.
- the lysine oxidase may be exogenously supplied.
- the tissue may be held together by any conventional means, such as sutures, tape, stapes and the like.
- the agent also can be in a vehicle such as a microparticle (e.g. a microsphere, a microcapsule, or a nanosphere), the microsphere or microcapsule being rich in lysines, or glutamines and lysines, whereby the microparticle can be attached to a body tissue.
- a microparticle e.g. a microsphere, a microcapsule, or a nanosphere
- the microsphere or microcapsule being rich in lysines, or glutamines and lysines, whereby the microparticle can be attached to a body tissue.
- a method is provided of treating a subject to attach microparticles to a body tissue of the subject comprising contacting the body tissue with lysine oxidase in an amount effective to permit crosslinking of the microparticles to the body tissue, contacting the body tissue with microparticles having surface available reactive groups in an amount sufficient to attach the microparticles to the body tissue in the presence of lysine oxidase, and allowing the microparticles to remain in contact with the body tissue for a time sufficient to permit a layer of microparticles to covalently attach to the body tissue.
- the body tissue is an external surface such as a skin surface, nails or hair.
- the lysine oxidase is exogenous.
- the reactive groups are surface available in an amount sufficient to attach the microparticle to a skin surface in the presence of exogenous lysine oxidase.
- the surface available reactive groups are selected from the group consisting of amines, aldehydes, aliphatic amines or lysines. If the microparticles are to act as substrates of lysine oxidase, then the surface available reactive groups are preferably lysines. If the microparticles are to react with lysine oxidase products, then the surface available reactive groups are preferably amines or aldehydes.
- the layer of microparticles is non-planar.
- the microparticles further comprise an agent.
- the agent may be an active agent, but it is not so limited.
- the agent is a non-nucleic acid active agent, while in another embodiment, it is a non-protein active agent.
- the agent is a protein agent.
- the active agent is selected from the group consisting of a cosmetic agent, a bulking agent, a hair conditioning agent, a hair fixative, a sunscreen agent, a moisturizing agent, a depilatory agent, an anti-nerve gas agent, a film forming agent, a vitamin, an insect repellant, a coloring agent, a pharmaceutical agent, a ligand-receptor complex and a receptor of a ligand-receptor complex.
- the active agent is not itself a substrate of lysine oxidase.
- the agent is not itself able to react with lysine oxidase products.
- An agent which is not able to react with lysine oxidase products is defined herein as an agent which lacks both amine and aldehyde groups.
- the agent is an enzyme.
- the enzyme may be an enzyme that degrades nerve agent and may be selected from the group consisting of OPAA anhydrolase and squid type OPA anhydrase.
- the microparticles further comprise a synthetic polymer.
- the synthetic polymer may be latex or polystyrene, but is not so limited.
- the microparticles are porous. In yet another, they are hollow.
- the microparticles have a size selected from the group consisting of greater than 5 ⁇ m, less than 5 ⁇ m, less than 1 ⁇ m, 100 nm to 500 nm, less than 100 nm, 20 nm to 90 nm, 20 nm to 35 nm, less than 20 nm, 1 nm to 10 nm, and 5 nm to 10 nm. These sizes or ranges can be cut offs or can represent average size determinations.
- the microparticles may be non- biodegradable. In some preferred embodiments, they are water insoluble. In some even more preferred embodiments, they are detergent insoluble. In some embodiments, the microparticles enter the cornified layer of the skin but not the layer of living cells. However, in these latter embodiments, the agent contained within the microparticle may be able to enter the layer of living cells.
- the reactive groups are part of a polymer.
- the polymer may be covalently attached to the microparticle.
- the polymer may be comprised of units at least 20%, at least 30%>, at least 40%, or at least 50% of the units carrying reactive groups, wherein the reactive groups are selected from the group consisting of amines, aldehydes, aliphatic amines and lysines.
- the polymer is rich in reactive groups at a surface available terminus, anywhere from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, or more units long, or at a surface available loop.
- the polymer comprises a polymer selected from the group consisting of at least two contiguous linked units each carrying reactive groups, at least three contiguous linked units each carrying reactive groups, at least four contiguous linked units each carrying reactive groups, at least five contiguous linked units each carrying reactive groups, at least ten contiguous linked units each carrying reactive groups, at least fifteen contiguous linked units each carrying reactive groups, and at least twenty contiguous linked units each carrying reactive groups.
- the reactive groups in a polymer are the same (i.e., they are all lysines, all amines, all aliphatic amines, or all aldehydes).
- the invention provides, in yet other aspects, compositions of microparticles and kits thereof.
- compositions of microparticles and kits thereof are equally applicable to the following microparticle composition and kit aspects of the invention.
- the invention provides a composition having a microparticle comprising an agent and a polymer rich in amine or aldehyde reactive groups, wherein the amine or aldehyde reactive groups are surface available in an amount sufficient to attach the microparticle to a skin surface in the presence of lysine oxidase.
- the lysine oxidase is exogenous, and in another it is endogenous.
- the reactive groups are surface available in an amount sufficient to attach the microparticle to a skin surface in the presence of endogenous lysine oxidase. In another embodiment, the reactive groups are surface available in an amount sufficient to attach the microparticle to a skin surface in the presence of exogenous lysine oxidase.
- the invention provides a composition comprising a microparticle having a non-nucleic acid active agent, and covalently attached surface available reactive groups, wherein the microparticle is 100 nm to 500 nm in size, or other sizes as described herein.
- the surface available reactive groups are free pendant groups.
- agents may be derivatized to possess hydrazide reactive groups which react with aldehydes.
- Figure 1 depicts a kit according to the invention.
- the agents are chemical agents and include, but not are limited to, pharmaceutical agents, enzymes, cosmetics, sunscreen agents, ligands of ligand-receptor pairs, receptors of ligand-receptor pairs, components of high affinity noncovalent bonding pairs, insecticides and repellants, bactericides, fungicides, tissue sealants, labels, structural proteins, chelating agents and the like.
- the agent is an anti -nerve gas agent.
- the agent may be an enzyme that degrades nerve agents and as such may be selected from the group consisting of OPAA anhydrolase and squid type OPA anhydrase. Examples of other agents useful in the invention are listed below.
- active agent it is meant that the agent, once coupled to a biological tissue in vivo or in vitro, has, maintains or can be released to have a desired activity such as a desired biological activity or therapeutic activity.
- active agents are pharmaceutical agents, sunscreen agents, insecticides, bactericides, fungicides, etc.
- the agents are linked to proteinaceous material.
- the agents When used in vivo, the agents are attached to a body tissue. Particularly important body tissues as sites of attachment are the integument (including specifically skin, nails, hair, mucous membranes and the surface of the eye), internal organs, internal tissue and wound beds.
- the tissue may be a body tissue, a tissue or cell isolate, isolated proteins, synthetic proteins, cell cultures and the like for use, for example, in assay systems according to the invention.
- the body tissue is skin, nails, and hair.
- conjugates of agents and linkers are applied, for example, to body tissue and covalently linked to that tissue using lysine oxidase.
- lysine oxidase functions, in important embodiments, to prepare lysines for spontaneous bond formation in subsequent aldol condensation or Schiff base reactions.
- lysine oxidase in some preferred embodiments, is applied to a lysine containing material (such as the body tissue, the linker, the agent or the microparticle (as described below)) and allowed to generate reactive aldehydes from the lysine amine groups. Once these reactive aldehydes are generated (or formed), they can spontaneously react with other substances that contain amines or aldehydes, to form covalent crosslinks.
- linking means two entities stably bound to one another by any physiochemical means. It is important that the nature of the attachment be of such a nature that it does not impair substantially the effectiveness of the agent or the substrate binding ability of the linker. Keeping these parameters in mind, any linkage known to those of ordinary skill in the art may be employed, covalent or noncovalent. Covalent is preferred. Such means and methods of attachment are well known to those of ordinary skill in the art. An agent attached to a linker according to the invention is therefore a conjugate.
- agents used according to the invention are not themselves, in their native form, substrates for lysine oxidase nor can they spontaneously react with lysine oxidase products.
- Such agents can be modified according to the invention to render the agent so. This may be accomplished for example by adding an amine or an aldehyde side group(s) to an appropriate peptide moiety of the agent (i.e., a "modified” agent) or by covalently coupling an amine or aldehyde containing substance (such as lysine or polylysine) to the agent to form a conjugate that is useful.
- the most preferred method is to couple polylysine, to the agent to form an appropriate conjugate.
- Such a conjugate could function as a substrate for lysine oxidase and, as well, it could spontaneously react with a lysine oxidase product.
- the agent is preferably modified to contain aldehydes or it is conjugated to an aldehyde containing substance.
- the most preferred linkers are polymers rich in lysine.
- a polymer rich in lysine is a molecule wherein at least 20% of the units of the polymer are lysine, or wherein the molecule includes at least 3, preferably 4 and most preferably 5 contiguous, linked lysines. It should be understood, however, that as few as one or two lysines can be attached to or tethered to an agent to render the agent a substrate of lysine oxidase. Similar definitions apply to substances, including polymers, that are rich in amines or aldehydes. Polymers rich in amines and aldehydes but not lysines are preferred in some embodiments. In other embodiments, polymers rich in both amines and aldehydes are useful. Depending upon the embodiment and use, these latter polymers may not, preferably, contain lysines.
- the invention in one aspect involves attaching active agents to proteinaceous materials using lysine oxidase, wherein the native agent itself is a substrate of lysine oxidase.
- active agents typically will be polypeptides or proteins and most typically will contain reactive lysines.
- a simple screening method is employed.
- the screening method involves selecting an agent or an active agent, applying to or exposing the active agent to lysine oxidase and applying to the treated agent a detectable label known to spontaneously react with lysine oxidase products. Then it is determined whether the agent covalently binds to the detectable label.
- a similar assay for determining whether a linker is a substrate of lysine oxidase is also envisioned and embraced by the invention.
- substrates that react spontaneously with lysine oxidase products can be similarly identified with only routine experimentation.
- conjugates it may be desirable to vary not only the number of lysines or amines or aldehydes in the linker, but it also may be desirable to tether the linker to the active agent via a spacer. This can remove, for example, any problems that might arise from steric hindrance, wherein access by lysine oxidase to the reactive linker is hindered.
- spacers can be any of a variety of molecules, preferably nonactive, such as straight or even branched carbon chains of C ⁇ -C 30 , saturated or unsaturated, phospholipids, amino acids, and in particular glycine, and the like, naturally occurring or synthetic.
- Additional spacers include alkyl and alkenyl carbonates, carbamates, and carbamides. These are all related and may add polar functionality to the spacers such as the C ⁇ -C 30 previously mentioned.
- the conjugations or modifications described herein employ routine chemistry, which chemistry does not form a part of the invention and which chemistry is well known to those skilled in the art of chemistry.
- the use of protecting groups and known linkers such as mono and heterobifunctional linkers are well documented in the literature and will not be repeated here.
- Attachment according to the invention thus need not be directed attachment.
- the components of the compositions of the invention may be provided with functionalized groups to facilitate their attachment and/or linker groups may be interposed between the components of these compositions to facilitate their attachment.
- the components of the compositions of the present invention may be synthesized in a single process, whereby the components could be regarded as one and the same entity.
- a protein agent may be synthesized recombinantly to include a polylysine at one end for linking the polypeptide via lysine oxidase.
- covalent bonds for attaching agents to linkers include those wherein bifunctional crosslinker molecules are used.
- the crosslinker molecules may be homobifunctional or heterobifunctional, depending upon the nature of the molecules to be conjugated.
- Homobifunctional crosslinkers have two identical reactive groups.
- Heterobifunctional crosslinkers are defined as having two different reactive groups that allow for sequential conjugation reaction.
- Various types of commercially available crosslinkers are reactive with one or more of the following groups: primary amines, secondary amines, sulphydryls, carboxyls, carbonyls and carbohydrates.
- amine-specific crosslinkers are bis(sulfosuccinimidyl) suberate, bis[2-(succinimidooxycarbonyloxy)ethyl] sulfone, disuccinimidyl suberate, disuccinimidyl tartarate, dimethyl adipimate-2 HCl, dimethyl pimelimidate-2 HCl, dimethyl suberimidate-2 HCl, and ethylene glycolbis- [succinimidyl-[succinate]].
- Crosslinkers reactive with sulfhydryl groups include bismaleimidohexane, 1 ,4-di-[3'-(2'-pyridyldithio)-propionamido)]butane, 1 -[p- azidosalicylamido]-4-[iodoacetamido] butane, and N-[4-(p-azidosalicylamido)butyl]-3'-[2'- pyridyldithiojpropionamide.
- Crosslinkers preferentially reactive with carbohydrates include azidobenzoyl hydrazine.
- Crosslinkers preferentially reactive with carboxyl groups include 4- [p-azidosalicylamido] butylamine.
- Heterobifunctional crosslinkers that react with amines and sulfhydryls include N-succinimidyl-3-[2-pyridyldithio]propionate, succinimidyl[4- iodoacetyljaminobenzoate, succinimidyl 4- N-maleimidomethyl] cyclohexane-1-carboxylate, m-maleimidobenzoyl-N-hydroxysuccinimide ester, sulfosuccinimidyl 6-[3-[2- pyridyldithio]propionamido]hexanoate, and sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate.
- Heterobifunctional crosslinkers that react with carboxyl and amine groups include l-ethyl-3-[[3-dimethylaminopropyl]-carbodiimide hydrochloride.
- Heterobifunctional crosslinkers that react with carbohydrates and sulfliydryls include 4-[N- maleimidomethyl]-cyclohexane-l -carboxylhydrazide-2 HCl, 4-(4-N-maleimidophenyl)- butyric acid hydrazide-2 HCl, and 3-[2-pyridyldithio]propionyl hydrazide.
- the crosslinkers are bis-[ ⁇ -4-azidosalicylamido) ethyl]disulfide and glutaraldehyde. Amine or thiol groups may be added at any nucleotide of a synthetic nucleic acid so as to provide a point of attachment for a bifunctional crosslinker molecule.
- the nucleic acid may be synthesized incorporating conjugation-competent reagents such as Uni-Link AminoModifier, 3'-DMT-C6- Amine-ON CPG, AminoModifier II, N-TFA-C6-AminoModif ⁇ er, C6-ThiolModifier, C6- Disulfide Phosphoramidite and C6-Disulfide CPG (Clontech, Palo Alto, CA).
- conjugation-competent reagents such as Uni-Link AminoModifier, 3'-DMT-C6- Amine-ON CPG, AminoModifier II, N-TFA-C6-AminoModif ⁇ er, C6-ThiolModifier, C6- Disulfide Phosphoramidite and C6-Disulfide CPG (Clontech, Palo Alto, CA).
- the agent may be desirable to attach the agent to the linker by a bond that cleaves under normal physiological conditions or that can be caused to cleave specifically upon application of a stimulus such as light, whereby the agent can be released.
- the agent may be inactive in its conjugated form and activated only when released.
- the agent would be released to exert an activity remote from its point of attachment to the body tissue.
- the agent would be released in a sustained fashion, to prolong the release of the agent versus an agent applied to tissue but not covalently coupled to the tissue.
- Readily cleavable bonds include readily hydrolyzable bonds, for example, ester bonds, amide bonds and Schiff s base-type bonds. Bonds which are cleavable by light also can be used.
- Noncovalent methods of conjugation may also be used.
- Noncovalent conjugation includes hydrophobic interactions, ionic interactions, biotin-avidin and biotin-streptavidin complexation and other affinity interactions.
- a molecule such as avidin is attached to a linker on a linking molecule such as polylysine.
- This conjugate once attached to tissue according to the invention, then becomes a universal linking moiety for any agent attached to a biotin molecule.
- the linker or linking molecules may be part of a microparticle such as a microsphere or a microcapsule and the agent may be contained in the microparticle, either physically entrapped therein, covalently bonded thereto or otherwise physiochemically attached to the microparticle.
- the microspheres or microcapsules carry, at least on their surface, polymers rich in amines, aldehydes, or lysines depending upon whether they are to act as lysine oxidase substrates or are to react spontaneously with lysine oxidase products.
- the methods for manufacturing microparticles according to the prior art are well documented and do not form a basis for the present invention. Examples of microspheres and microcapsules and their method of manufacture may be found in U.S. Patent 5,075,019, PCT WO95/24929, PCT WO94/23738 and PCT US96/11990, the disclosures of which are inco ⁇ orated herein by reference.
- microparticles of the present invention differ from those of the prior art, in part, in having surface available reactive groups such as lysines, amines, or aldehydes in an amount sufficient to crosslink to a body tissue. These microparticles, their method of manufacture and their uses are described in more detail below.
- the invention relates, in part, to the discovery that microparticles with particular surface characteristics can be linked to a tissue and can thereby effect an extended period of agent delivery to the tissue.
- the microparticles of the invention possess reactive groups on their surface (i.e., surface available reactive groups).
- Reactive groups include amine groups, such as those of lysine residues, aliphatic amine residues, such as those of lysine residues, lysines specifically, and aldehyde groups.
- the microparticles of the invention contain an active agent which when released from the microparticle provides prophylactic, therapeutic or cosmetic benefit to an external body surface with which it is in contact.
- the microparticles of the invention are preferably intended for use on an external body surface such as skin, hair or nails.
- microparticles which remain attached to the external surface and which do not degrade substantially throughout the course of treatment (e.g., days or weeks) are most useful in the invention.
- Any microparticle that contains an agent (as described herein) and that can hold (as a result of the covalent binding described herein) and release the agent onto an external surface (e.g., a skin surface) for a period of time sufficient for the agent to achieve its prophylactic, therapeutic or cosmetic pu ⁇ ose is useful in the invention.
- Microparticles commonly effect delivery of agents by way of diffusion, or by degradation or erosion. Examples of diffusional systems in which the active agent permeates at a controlled rate from a polymer are described in U.S.
- Patents 3,854,480, 5,133,974 and 5,407,686 Examples of erosional systems in which the active agent is contained within a matrix which in turn erodes with time are described in U.S. Patent 4,452,775, 4,675,189 and 5,736,152.
- biodegradable refers to the ability of a substance (in this case, a microparticle) to degrade in vivo, (i.e., upon contact with external surfaces such as the skin).
- biodegradable microparticles are made from polymers having bonds which are easily hydrolyzed once in contact with a physiological environment.
- the microparticle contains at least the agent, and even more preferably, it contains surface available reactive groups such as those described herein.
- Covalent linkage of the microparticle to the skin, hair or nails is desired. It is the covalent linkage which keeps the microparticles on the skin for the desired time, preferably in a layer, to achieve uniform and extended release of the active agent as desired. If the microparticles degrade too quickly, or degrade when contacted with a detergent such as soap, then the uniform distribution and extended release will be undermined. If degradation is slow or if degradation can occur independent of covalent attachment (such as degradation within a shell), then degradation can be acceptable. Thus, biodegradable microparticles are embraced by some aspects of the invention.
- the biodegradable microparticles degrade substantially only after the period of time corresponding to the treatment (e.g., days or weeks) in order to ensure sufficient delivery of the active agent to the skin surface.
- Microparticles that are differentially biodegradable are also useful in the invention.
- “differentially biodegradable” microparticle is one which does not degrade uniformly throughout its volume. It may instead degrade initially in an internal or core region, as an example. Internally degradable microparticles may be formed by coating biodegradable cores with non-biodegradable porous films or shells. The microparticle may alternatively degrade from the outer surface, however, it would still be necessary that a sufficient amount of reactive groups remain covalently attached at the surface, and/or extending within the microparticle, even throughout the portion of the degradation process during which covalent attachment of the microparticle is desired. This can be achieved, for example, by a microparticle which is covalently crosslinked internally.
- the microparticles are substantially non-biodegradable at their point of attachment to the skin surface over the period of time during which covalent attachment is desired.
- Another type of microparticle which is useful to the invention is one which is non- biodegradable.
- a non-biodegradable microparticle is one which does not degrade upon- exposure to a physiological environment or temperature. As mentioned above, such non- biodegradable particles release active agent by diffusion. It is preferred that a subset of microparticles having amine or aliphatic amine groups be non-biodegradable.
- the microparticles are substantially non-biodegradable during the treatment period, which may last for several days to several weeks or completely non-biodegradable.
- the microparticles will simply be sloughed off along with the dead skin cells to which they are attached.
- the outermost portion of the skin to which the microparticles will be attached in some instances is not living and is sloughed off and replaced completely every 10 to 14 days.
- the microparticles of the invention may be synthesized using naturally occurring or non-naturally occurring polymers.
- Non-naturally occurring polymers are referred to herein as synthetic polymers.
- Naturally occurring polymers include nucleic acids, peptides, polypeptides, carbohydrates, alginate, polysaccharides (e.g., dextran, cellulose and glycogen), lipopolysaccharides, chitosan, chitin, peptidoglycans, starch, glycosaminoglycans, collagen, rubber (cis-l,4-polyisoprene), guayule (Parthenium argentatum), collagen, chemical derivatives thereof (substitutions, additions of chemical groups, for example, alkyl, alkylene, hydroxylations, oxidations, and other modifications routinely made by those skilled in the art), albumin and other hydrophilic proteins, zein and other prolamines and hydrophobic proteins, copolymers and mixtures thereof.
- the microparticles may further comprise one or more synthetic polymers or copolymers.
- synthetic refers to a substance which is not naturally occurring.
- Exemplary synthetic polymers include, but are not limited to, polyamides, polycarbonates, polyalkylenes, polysulfones, poly(2-sulfobutyl-vinyl alcohol)-graft-poly(D,L- lactic-co-glycolic acid), poly-hydroxyalkanoates, polyalkylene glycols, polyalkylene oxides, polyalkylene terepthalates, polydimethylsiloxane polyvinyl alcohols, polyvinyl ethers, polyvinyl esters, polyvinyl halides, silicones, polyglycolic acid (PGA), polylactic acid (PLA), copolymers of lactic and glycolic acids (PLGA), polyanhydrides, polyorthoesters, polyvinylpyrrolidone, polyglycolides, polysilox
- Still other microparticles may be comprised of chimeric polymers of synthetic and naturally occurring residues.
- Chimeric polymers refer to polymers of different residues or units.
- a chimeric polymer may contain amino acid and non-amino acid residues, or it may contain natural and synthetic residues.
- a residue in a polymer refers to (and may be used interchangeably with) a unit of a polymer.
- Examples of a polymer residue i.e., a polymer unit
- examples of a polymer residue include an amino acid in a peptide and a nucleotide in a nucleic acid.
- Non-amino acid residues such as saccharides, fatty acids, sterols, isoprenoids, purines, pyrimidines, derivatives or structural analogs of the above, or combinations thereof and the like may be used.
- Non-naturally occurring non-amino acid substitutes include but are not limited to 2-azetidinecarboxylic acid, pipecolic acid, S- ethylisothiourea, 2-NH -thiazoline and 2-NH -thiazole.
- the natural, synthetic and chimeric polymers may themselves be biodegradable or non-biodegradable, as intended herein.
- biodegradable polymers include synthetic polymers such as polymers of lactic acid and glycolic acid, polyanhydrides, poly(ortho)esters, polyurethanes, poly(butic acid), poly(valeric acid), and poly(lactide- cocaprolactone), and natural polymers such as those listed herein. In general, these materials degrade either by enzymatic hydrolysis or exposure to water in vivo, by surface or bulk erosion.
- the polymers may optionally be in the form of a hydrogel that can absorb up to about 90% of its weight in water and further, optionally may be crosslinked with multivalent ions or other polymers.
- non-biodegradable synthetic polymers examples include latex, polystyrene, polystyrene derivatives, poly-N-ethyl-4-vinylpyridinium bromide, silicone, polypropylene, ethylene vinyl acetate, poly(meth)acrylic acid, polymethylacrylate, polyamides, copolymers and mixtures thereof.
- U.S. Patent 5,861,149 discloses methods for making non-biodegradable microparticles which can be used in the present invention.
- Polystyrene particles useful in the invention are commercially available from a variety of manufacturers including Polysciences, Inc. (Warrington, PA), Seradyn (Indianapolis, IN) and Dynal.
- the microparticles may also be formed from or may include non-polymer moieties such as lipids including sterols such as cholesterol, cholesterol esters and fatty acids or neutral fats such as mono- di- and tri-glycerides.
- the microparticles may be made from organic and/or inorganic substances.
- the majority of polymers listed above are organic.
- inorganic substances include but are not limited to polyphosphate, zirconia-silica (ZS), Si(OC 2 H 5 ) , Al(NO 3 ) 3 x 9H 2 O, AgNO , HNO 3 , poly(phenylphosphinoborane) (an inorganic analogue of polystyrene) and PRIMM.
- the polymer and non-polymers which make up the microparticles may be crosslinked, but need not be.
- Suitable crosslinking agents include those listed above.
- a wide variety of crosslinking agents suitable to the various chemistries of the microparticles described herein are commercially available from manufacturers such as Pierce Chemical Co. (Rockford, IL) and Sigma Aldrich (St. Louis).
- the microparticles may be predominantly composed of one or more polymers.
- a blend of natural and synthetic polymers may be used in microparticle synthesis.
- the microparticles may have an external coating composed of the same or a different polymer or non-polymer substance.
- the microparticle may be composed internally of polystyrene and an active agent and may have an exterior coating (preferably covalently attached) of a substance rich in reactive groups (as discussed below).
- more than one polymeric or non-polymeric substance, or a combination thereof may be commingled prior to microparticle formation, resulting in their combined presence both internally and on the external surface of the microparticle.
- microparticle embraces particles, spheres and capsules of both nanometer and micrometer sizes (i.e., microparticles, microspheres, nanoparticles, nanospheres, microcapsules and nanocapsules).
- the microparticles may adopt a variety of shapes including regular shapes such as spheres and ellipses as well as non-regular shapes. Additionally, the surface may be, but need not be, smooth.
- the microparticles may be hollow with the agent stored in the core of the shell, in which case, they may be referred to as microcapsules or nanocapsules.
- porous microparticles are one having internal, potentially interconnected channels (or pores) which are preferably open to the external surface of the particle.
- Methods for synthesizing hollow and porous microparticles are well known in the art.
- Porous microparticles are generally made by the inclusion of a porogen during microparticle synthesis followed by its removal (e.g., through dissolution in an appropriate solvent) and subsequent replacement with a solution containing the active agent.
- the porous microparticles may additionally have a coat comprising reactive groups (as described below), while being internally void of these groups.
- the microparticle be less than five microns in size (i.e., any single dimension of the microparticle is less than 5 microns).
- the microparticle should be small enough so as to feel smooth when applied to the external body surface.
- the microparticles or their surface available reactive groups are capable of penetrating the external surface, preferably up to, but not including, the layer of living cells.
- the average size of the microparticle is less than 1 micron but greater than 100 nm, and in others, it is 100 nanometers to 500 nanometers. In still other embodiments, the average size of the microparticles is less than 100 nm in size, 20 nm to 90 nm in size, or 20 nm to 35 nm in size. These smaller particle sizes may be preferred when particle penetration of the skin is desired. In most instances, it may be undesirable for the microparticles to penetrate the living layer, and it is therefore intended that the microparticle remain in the cornified layer. It is believed that microparticles less than 1 nm, as well as others that are less than 5 nm could penetrate to the living layer, and thus should be avoided in most instances.
- the particles may enter the cornified layer and thereby release their active agent which may diffuse into and thereby enter the living layer.
- microparticles of an average size of 1 nm to 20 nm, I nm to 10 nm, and in particular 5 nm to 10 nm may be desirable in some aspects of the invention. It is well within the realm of the ordinary artisan to determine the size of particles which are best suited to the various embodiments recited herein. It also should be noted that size may be uniform as in all the particles being of a certain size or range or size may be mixed.
- all the microparticles should be at least a certain size (e.g., at least 100 nm). If it is desired that all microparticles penetrate the outer most surface of the epidermis, then all should be no larger than a certain size (e.g., no larger than 100 nm). It also may be desired to have a variety of sizes whereby the microparticles will penetrate to different extents depending on size, thereby forming a three dimensional "layer". Size will depend upon factors such as the agent to be delivered, the condition being treated, the desired length of treatment, and other such factors well known to those of ordinary skill in the art. Appropriate size can be determined by no more than routine experimentation, trying different sizes to select the one or ones that are ideal for a particular pu ⁇ ose.
- the microparticles are generally intended to be linked to proteinaceous material.
- the microparticles When used in vivo, the microparticles are attached to a body tissue.
- Particularly important body tissues as sites of attachment are the integument (including specifically skin, nails, hair, mucous membranes and the surface of the eye), internal organs, internal tissue and wound beds.
- the tissue may be a body tissue, a tissue or cell isolate, isolated proteins, synthetic proteins, cell cultures and the like for use, for example, in assay systems according to the invention.
- the body tissue is a skin, nail or hair surface.
- the microparticles are water insoluble and, preferably, detergent insoluble (i.e., neither the microparticle nor the bond between the microparticle and the external surface are adversely affected by exposure to detergents, such as hand, body and hair soap).
- detergent insoluble i.e., neither the microparticle nor the bond between the microparticle and the external surface are adversely affected by exposure to detergents, such as hand, body and hair soap.
- Many of the organic polymers listed herein are water insoluble. It is well within the realm of the ordinary artisan to determine which of these are preferred for making water insoluble particles.
- One way of making microparticles detergent insoluble is by crosslinking.
- the reactive groups necessary to the invention i.e., the amines, aldehydes, and lysines
- a crosslinking agent be used which does not involve these reactive groups or that the reactive groups be attached to the microparticle after such crosslinking.
- the microparticles can be made more resilient to detergent treatment by the inco ⁇ oration of fluorinated steroids as taught in U.S. Patent 4,927,687.
- the microparticles must possess reactive groups.
- Reactive groups include aldehydes, amines, and aliphatic amine groups.
- the reactive groups may be provided by any moiety which contains them, including, but not limited to, peptides, polypeptides and proteins.
- reactive groups be accessible to the body tissue (e.g., the skin) to which the microparticles are to be bound.
- the reactive groups must be sufficiently exposed, and the "backbone” to which they are attached preferably sufficiently flexible, to react with and form a covalent bond with reactive groups on the contacted surface.
- Reactive groups which are present on the surface of the microparticles are likely to be accessible, and thus such "surface available” reactive groups are generally preferred.
- Surface available reactive groups may be "free” or "fixed.” Free surface available reactive groups include those which are present on a free, unconstrained end of a polymeric or non-polymeric substance, present at the surface of the microparticle.
- the free, unconstrained end of the polymeric or non-polymeric substance may be any length, provided the reactive groups contained therein are capable of reacting with the skin. Free reactive groups also embrace those which are non-complexed. A non-complexed reactive group is one which is not in physical association with another moiety to the extent that it is precluded from contacting and being covalently attached to a reactive group on, for example, the skin. Fixed reactive groups may also be useful in the invention, provided they are sufficiently flexible to bind to skin surface reactive groups. Thus, a reactive group may be present in a loop of a polymer the ends of which are both bound to the surface of the microparticle. As long as the loop is long enough and flexible enough to allow the reactive groups to contact and react with the skin surface, this type of "fixed reactive group" will be useful.
- the surface available reactive groups must also be present in an amount sufficient to attach covalently the microparticles to the skin in the presence or absence (but at least pretreatment with) of lysine oxidase.
- Lysine oxidase may be supplied exogenously (i.e., exogenous lysine oxidase) or it may be endogenous to the tissue (i.e., endogenous lysine oxidase).
- the source of lysine oxidase plays an important role in the amount of surface available reactive groups that are sufficient to link the microparticle to an external surface (and in the size of the microparticle, as discussed above). Exogenously supplied lysine oxidase may be supplied in quantities exceeding those which are available endogenously.
- the amount of surface available groups sufficient for linking will generally be higher than that amount sufficient for linking using exogenous lysine oxidase.
- microparticles Polymeric and non-polymeric substances from which the microparticles are synthesized may inherently possess the necessary reactive groups, or they may be derivatized either prior to or following microparticle formation to possess such groups.
- the microparticles may be formed of substances lacking reactive groups (e.g., polystyrene) and then coated with a substance which contains these groups.
- the reactive groups may also be linked to the surface of the microparticle after microparticle formation.
- the surface may be prepared or treated to contain carboxamide residues, after which it is exposed to an excess of an aliphatic amine - containing polymer (e.g., present in a lysine-rich polymer) in the presence of limited quantities of transglutaminase. It is likely that even after binding of the carboxamide residues to the aliphatic amines in a 1 :1 ratio, an excess of aliphatic amine reactive groups will still be present on and pendant from the surface of the microparticle.
- Polymers rich in the necessary reactive groups also can be covalently attached at a terminal end to the microparticle using homo and heterobifunctional crosslinkers. Useful crosslinkers are as described and listed herein.
- such polymers can be tethered to the surface of a microparticle by hydrophobic bonding tethers covalently attached to the polymer and hydrophobically attached to the microparticle.
- the manufacture of such microparticles is well within the realm of the ordinary artisan.
- the methods for manufacturing a variety of microparticles according to the prior art are well documented.
- the present invention differs from those of the prior art, in part, in that the polymers or non-polymers of the microparticle themselves contain or are derivatized to contain amine aldehyde groups and/or lysines, especially at the surface, where they are available for covalent bonding to the skin.
- Preferred polymers are polymers bearing multiple reactive groups that are substrates of lysine oxidase or that react with lysine oxidase products.
- Aliphatic amines that are substrates of lysine oxidase also are well known and are included in albumin and polylysine, for example.
- the present invention involves in one aspect using a plurality of, for example, aliphatic amines spaced apart at discrete intervals, preferably along the length of a branched or unbranched polymer.
- a further embodiment involves microparticles comprising polymers having multiple units, which each bear a reactive group in the form of an aliphatic amine or an amine or an aldehyde or a lysine.
- the polymer can be a homopolymer or a heteropolymer.
- Polymers include polymers which contain at least three reactive groups spaced apart from one another at discrete intervals along the backbone of the polymer, separated by one or more backbone atoms. This is most easily envisioned, for example, with polymers rich in lysine, whereby discrete units of the polymer carry the aliphatic amine, each being separately a substrate for lysine oxidase.
- the polymer may comprise or in some instances consist solely of contiguous lysines, preferably at least 3, at least 4 and at least 5 such contiguous lysines. Polymers of contiguous units, each carrying, for example, an aliphatic amine, are preferred. The same is the case for amines and aldehyde.
- polystyrene resin Another category of preferred polymer is those rich in amines, aldehydes, or aliphatic amines, such as lysine.
- a polymer rich in lysine is a molecule wherein at least 20% of the units of the polymer carry an aliphatic amine, or wherein the molecule includes at least 3, preferably 4 and most preferably 5 separate and discretely spaced by a regular distance aliphatic amines, such as occurs with contiguous, linked lysines.
- the polymer includes at least 10, at least 15 or at least 20 separate and discretely spaced aliphatic amines.
- a chain of as few as two lysines can be attached to or tethered to an microparticle to render the microparticle a "substrate" of lysine oxidase.
- the polymers may also contain at least 30%>, at least 40%, at least 50% or more of lysine, depending upon the embodiment.
- Other preferred polymers containing amines (but not lysines or aliphatic amines) or aldehydes are similarly defined.
- microparticles it may be desirable to vary not only the number of surface available reactive groups, but it also may be desirable to tether the reactive groups to the microparticle via a spacer. As discussed earlier, this can remove, for example, any problems that might arise from steric hindrance, wherein access by, for example, lysine oxidase, to the reactive group directly on the surface is hindered. Similarly, the tether can facilitate the reaction between reactive aldehydes on the surface and amines or aldehydes on another, regardless of which are present on the microparticle.
- the polymers may also have termini (either amino or carboxy) that are predominantly rich in reactive groups.
- the termini are located on the surface of the microparticle.
- the terminus may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 or more units at a terminal end of a polymer.
- the reactive group rich stretch of the polymer may also be located on a "loop" of a polymer which is present at the surface of a microparticle.
- microparticles including phase separation, solvent evaporation, emulsification and spray drying.
- the following examples are intended to provide guidance in the synthesis of some microparticles of the invention, but are not to be construed as limiting the invention in any way.
- These examples describe how to make microparticles that act as substrates of lysine oxidase. It is well within the realm of the ordinary artisan to apply such teachings to the manufacture of particles that, rather than being substrates of lysine oxidase, react with lysine oxidase products, without undue experimentation.
- Encapsulated microspheres made from poly(lactide-co-glycolide) and poly( ⁇ -CBZ-L- lysine) and subsequently treated so as to expose surface reactive amino groups have been reported previously. (Zheng and Hornsby, 1999, Biotechnol. Prog. 15:763-767)
- the microspheres are formed using double-emulsification/solvent evaporation (Alonso, et al., 1993, Pharmacol. Res. 10:945-953)
- the carbobenzoxy (i.e., CBZ) protective groups are removed using either acid hydrolysis or lithium/liquid ammonia reduction, thereby exposing reactive amine groups.
- Lithium/liquid ammonia reduction is recommended if microsphere are desired, given its less harsh effect of the external surface of the microparticle.
- the lithium treatment was reported to be more effective in producing surface reactive amino groups than was the acid hydrolysis procedure. If a solid surface particle (i.e., a microsphere) is desired, the lithium treatment may be preferred. In this latter method, the active agent may be added during the formation of the microparticles since the lithium treatment reportedly does not create pores in the surface of the particles and thus will not adversely affect the agent. If, on the other hand, a surface porous particle is desired, then the acid hydrolysis method may be preferred, provided the agent is either resistant to the acid treatment or is loaded into the particles following acid treatment.
- a similar strategy may be used to produce non-biodegradable microparticles, by substituting poly(lactide-co-glycolide) with a non-biodegradable polymer such as those disclosed herein.
- a copolymer of lysine and a synthetic polymer such as, for example, poly(lactic acid-co-lysine) may be used alone to form the microparticles followed by mild acid hydrolysis or lithium treatment.
- Such lysine containing copolymers have been manufactured previously. (Barrera, et al., 1993, J. Am. Chem. Soc.
- microparticles may be made using the technique of Zheng and Hornsby but excluding poly-lysine. After being formed, the microparticles may be coated with a solution of poly( ⁇ -CBZ-L-lysine).
- Commercially available microparticles such as those made from polyacrylamide, polyacrylate, polystyrene, or latex (Bio-Rad Laboratories (Richmond, CA), LKB Mather (Stockholm, Sweden)) or those made from natural polymers such as agarose, crosslinked agarose, globulin, and liposomes (Bio-Rad Laboratories (Richmond, CA), Pharmacia (Piscataway, NJ), IBF (France)) can also be coated with CBZ- protected as well as non-protected lysine containing polymer solutions following agent loading.
- Microcapsule coating methods are known in the art. Whether a microparticle so generated according to the teachings herein is a substrate of lysine oxidase or whether it is so able to react with a lysine oxidase product can be determined using the assays described herein for linkers and agents. Preferably, the microparticle is loaded with a detectable label such as a fluorescent dye or a fragrance. As applied to the screening assay, it is recommended that the labeling agent is covalently fixed to the microparticle such that no label escapes from the microparticle.
- any label detected on the external surface is indicative of a microparticle that is bound to the surface rather than a label which has exited a microparticle which itself was not capable of binding to the surface.
- the surface may be additionally washed with water and/or a detergent and then again tested for the presence of the microparticle.
- the amounts of materials and conditions employed for these assays are derivable from the examples below and, in general, can be derived by those of ordinary skill in the art without undue experimentation from, for example, the publication by Kahlem, et al., Proc. Natl. Acad. Sci, USA, Vol. 93, pp. 14580-14585, December, 1996.
- the microparticle Prior to contact with the body tissue, the microparticle is loaded with an agent, either physically entrapped therein, covalently bonded thereto or otherwise physiochemically attached to the microparticle.
- the agent may be inco ⁇ orated (i.e., "loaded") into the microparticle either at the time of, or after, microparticle formation, depending upon whether the microparticle formation process would be deleterious to the active agent.
- the agent may be an active agent.
- active agent it is meant that the agent, once coupled to a biological tissue (such as skin) in vivo or in vitro, either directly or indirectly via a microparticle, has, maintains or can be released to have a desired activity such as a desired physiological, prophylactic, therapeutic or cosmetic activity.
- active agents are pharmaceutical agents, sunscreen agents, insecticides, bactericides, fungicides, etc.
- the active agent is not a labeling agent such as a diagnostic agent.
- the agent is not a cosmetic agent.
- the active agent is a non-nucleic acid active agent.
- a non-nucleic acid active agent refers to an active agent which is not a nucleic acid.
- the active agent is a non-protein active agent.
- a non-protein active agent is an active agent which is not a protein (i.e., it is not composed exclusively of peptide linkages of amino acid residues or units).
- the agents can be selected from the lists provided herein.
- the agent is a noncorneocyte, nonlabeling active agent.
- corneocyte proteins specifically excluded in these particular embodiments are corneocyte proteins.
- the agent also is a non-extracellular matrix protein agent.
- a non-extracellular matrix protein agent is one that is not an extracellular matrix protein.
- a nonlabeling active agent is one that is not simply a passive label with no function, when applied to a body tissue, other than being a label.
- specifically excluded in some embodiments are labeled corneocyte proteins, labeled fibronectin, labeled extracellular matrix proteins, putrescine, dansylcadaverine, 5-(biotinamido)-pentylamine, fluoresceincadaverine and the like.
- the active agent may be linked to the natural, synthetic or chimeric polymer or non- polymer of the microparticle.
- Such linkage may be covalent in nature.
- any linkage between the active agent and another component of the microparticle is characterized by a bond that cleaves under normal physiological conditions or that can be caused to cleave specifically upon application of a stimulus such as light, whereby the agent can be released. These bonds are as described herein. In other instances, the agent would be released to exert an activity remote from the point of attachment of the microparticle to the body tissue.
- the active agent is free and not linked to another component of the microparticle.
- the release of the active agent from the microparticle is dependent upon the flow of (physiological) fluids into the porous network of the microparticle, the dissolution of the active agent in such fluids and the exit of fluid and agent from the microparticle.
- the agent would be released in a sustained fashion.
- Active agents in an isolated form may also be used according to the invention. "Isolated” as used herein will depend upon the agent employed. In general, isolated means that the material is essentially free of other substances to an extent practical and appropriate for the intended use of the material. In the case of pharmaceuticals and cosmetics, the materials are likely to be substantially pure. In the case of proteins, the proteins are sufficiently pure and sufficiently free from other biological constituents of the host cells from which the proteins are derived so as to be useful in the methods according to the invention. Typically, such active agents will be at least 95% or more pure.
- a native agent is one as it occurs in nature (isolated or synthesized to duplicate a naturally occurring molecule), without modification or conjugation as described herein.
- the body tissue, to which the microparticles are to be applied may be, but need not be, pretreated to facilitate the reaction with transglutaminase.
- Such treatments include washings, abrasive treatments including physical agents such as pumice, silica and oatmeal, enzymes such as papain, bromelins and the like and chemical agents such as alpha hydroxy acids and glycolic acids.
- the main object is to treat the body tissue so as to expose or create reactive glutamines and/or lysines.
- the body tissue may be pretreated by putting down a layer of reactive groups, such as by applying to the body tissue polymers rich in lysine, glutamine or both lysine and glutamine.
- lysine oxidase as part of the invention.
- polymers of lysine are described above. As used herein, such terms embrace nonpeptidic multimers of lysine whereby amino acid analogs are used to replace these amino acids in the or polylysine substrates.
- Some well known classes of peptide mimetics and pseudopeptides are: azabicycloalkane amino acids; thiazabicycloalkane amino acids; oxazabicycloalkane amino acids; diazabicycloalkane amino acids. D-amino acids are an important embodiment.
- the invention thus may be used, inter alia, to localize drugs to a tissue such as a wound bed or for localized delivery to a tissue, to hold a drug, insect repellant, bactericide fungicide, growth factors, cytokine, and the like at a particular location to prevent the drug from being flushed away to other body sites where it is not needed, to apply bulking agents and other cosmetic agents to the integuments, such as the skin, hair and nails, to hold sunscreen agents at the surface of the skin for longer periods of time, to hold anti-nerve gas enzymes at the surface of the skin whereby nerve gas can be deactivated, to hold or link chemical agents to the skin which can in turn act as binding sites for other agent or alternatively, as reactive sites for catalytic buildup of multiple alternating layers, to link hydrophobic compounds to the skin, thereby making the skin hydrophobic, to link conditioners to the hair, thereby giving hair the appearance of greater bulk and to provide agents to organs or tissues which are to be transplanted.
- a tissue such as
- lysine oxidase is used to glue two tissues to one another.
- Lysine oxidase, a substrate of lysine oxidase, or both can be supplied to the surfaces of two tissues which then are held in contact with one another for a period of time sufficient to permit lysine oxidase to crosslink the tissues to one another.
- exogenously supplied lysine oxidase is applied to the surfaces of the tissues to crosslink substrates of lysine oxidase to one another, which substrates are present and are endogenous on the surfaces of the tissue.
- exogenously supplied substrates of lysine oxidase are applied to the surfaces of the tissues and are acted upon by endogenous lysine oxidase to crosslink the tissue surfaces to one another.
- both lysine oxidase and substrate of lysine oxidase are applied to the surfaces of the tissue to crosslink the surfaces to one another.
- a single substrate such as polylysine could be applied, one end attaching to one surface and the other end attaching to the opposing surface of the tissues to be crosslinked to one another.
- a first substrate (a primary linking molecule) could be applied to create first reactive surfaces of a primary linking molecule (e.g. polylysine) and a second substrate (a secondary linking molecule complementary to the primary linking molecule) could be applied to crosslink the primary linking molecules on opposing surfaces to one another.
- the invention further provides methods of treating a subject to attach microparticles to a body tissue of the subject by contacting a tissue of the subject with lysine oxidase and with a microparticle having surface available reactive groups and allowing the lysine oxidase and the microparticles to remain in contact with the tissue for a time sufficient to permit a layer of microparticles to covalently attach to the tissue.
- the reactive groups are present on the surface of the microparticle in an amount sufficient to attach the microparticle to the skin surface in the presence of lysine oxidase or lysine oxidase products.
- the lysine oxidase may be endogenous (i.e., provided by the tissue to which the microparticle is applied) or exogenous.
- the quantity of surface available reactive groups which is a "sufficient amount" will vary depending upon whether the lysine oxidase is endogenous or exogenous, and, in some instance, on the number of lysine oxidase products on the tissue, as described above.
- a sufficient amount of surface available reactive groups can be achieved, for example, by increasing in the microparticles the number of residues which have the reactive groups, or by increasing in the microparticles (and particularly at the surface) the number of available reactive groups by preventing their chemical reaction with other reactive groups either intrinsic or extrinsic to the microparticle. Whether the particles have a "sufficient amount" of surface available reactive groups can be tested as described herein.
- the body tissue is an external surface such as skin, nails or hair. In important embodiments, the tissue is a skin surface.
- a subject may be a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat, rabbit or rodent. In all embodiments, human subjects are preferred.
- the subject to be treated according to the methods of the invention is one who will benefit from the treatment with the microparticles.
- Such treatment can be prophylactic, such as when the microparticles contain a sunscreen agent or a UV filter, or it can be therapeutic, such as when the microparticles contain an anti-fungal agent.
- the subject may be one in need of cosmetic benefit, in which case the microparticles may contain a cosmetic such as a moisturizer or a skin tanning agent.
- contacting refers to a physical interaction between the skin surface and the microparticles, or between the agents and the skin surface, or between the skin surface and the lysine oxidase, or, alternatively, the suspension in which the microparticles or agents are provided.
- "contacting” embraces placing, as an example, the agents, conjugates or microparticles in close enough proximity to the skin to allow for their attachment to the skin via their reactive groups.
- Agents, conjugates and microparticles may be applied to the skin alone, or alternatively, they may be provided together with a pharmaceutically acceptable carrier.
- the agents, conjugates and microparticles can be provided in a formulation commonly intended for application to an external surface, such as a lotion, gel, ointment, jelly, cream, shampoo, detergent or spray (e.g., aerosol).
- a formulation commonly intended for application to an external surface such as a lotion, gel, ointment, jelly, cream, shampoo, detergent or spray (e.g., aerosol).
- the agents, conjugates and microparticles may be provided together with lysine oxidase.
- agents, conjugates or microparticles After contacting the agents, conjugates or microparticles with, for example, the skin surface, it is necessary to allow the agents, conjugates or microparticles to remain in contact with the skin surface for a time sufficient to permit a layer of agents, conjugates or microparticles to covalently attach to the reactive groups (e.g., aldehydes) of the tissue.
- the agents, conjugates or microparticles When the agents, conjugates or microparticles are contacted with the skin surface they generally will distribute randomly throughout a volume above the skin surface, or if small enough in size, throughout a volume under the outermost layer of skin. This will also be the case should the agents, conjugates or microparticles be provided in a topical formulation such as an ointment.
- agents, conjugates or microparticles will contact the skin surface initially, however with time, a sufficient number of agents, conjugates or microparticles will settle closer to the skin surface until the point where their reactive groups will react with corresponding active groups on the skin, resulting in a covalent bond that tethers the agents, conjugates or microparticles to the skin. If the agents, conjugates or microparticles of small enough, they will distribute randomly below the outermost layer of skin and preferably in proximity to, but not within, the layer of living skin cells. As an example, a "sufficient number of microparticles" is that number required to provide an effective amount of the active agent to the tissue (e.g., the skin surface).
- agents, conjugates or microparticles whether applied to the tissue in an isolated form or as part of a formulation, are allowed to settle towards the tissue and thereby form a layer.
- a layer of agents, conjugates or microparticles is that amount and distribution of agents, conjugates or microparticles that is enough to provide distribution of active agent to the skin in amounts sufficient to achieve the prophylactic, therapeutic or cosmetic pu ⁇ ose of the agent.
- the agents, conjugates or microparticles need not be evenly adjacent to one another in the layer, nor must they be in the same plane (as described herein) provided their distribution above, within or below the outermost layer of skin allows the active agent to be distributed sufficiently.
- the active agent when the active agent is a sunscreen, it is desirable that it be applied uniformly distributed over an entire area of skin in order to provide maximal effect. It may not be necessary, however, that the sunscreen containing conjugates or microparticles be physically touching each other, provided each conjugate or microparticle is capable of providing sufficient amounts of sunscreen for a particular surface area.
- the active agent is a cosmetic, it may be desirable to form a layer of agents, conjugates or microparticles over a defined surface area in order to provide the cosmetic solely to the discrete area.
- the layer of agents, conjugates or microparticles may be a volume of space over the tissue occupied by the agents, conjugates or microparticles.
- the agents, conjugates or microparticles may be, but need not be, in a planar arrangement.
- a planar arrangement it is meant that the agents, conjugates or microparticles are equidistant from the surface of the tissue.
- a non-planar arrangement indicates that the agents, conjugates or microparticles are differentially spaced away from the surface of the tissue.
- the distance of the agents, conjugates or microparticles from the surface of the tissue may depend upon the location of the reactive groups which have covalently linked to the tissue. If these are located on long pendent chains, the agents, conjugates or microparticles may not be contacting the tissue surface at all.
- the method relies on the activity of endogenous lysine oxidase alone, then only the agents, conjugates or microparticles need be applied to the skin surface. However, if the method requires the use of exogenous lysine oxidase, then both agents, conjugates or microparticles, and exogenous lysine oxidase are applied to the skin surface and allowed to remain in contact with the skin for a time sufficient to permit the layer of agents, conjugates or microparticles to covalently attach to the skin.
- the lysine oxidase may be added before, simultaneously with, or after the agents, conjugates or microparticles. It is to be understood that the lysine oxidase may also act on the agents, conjugates or microparticles, rather than the tissue, and so may additionally be premixed with the agents, conjugates or microparticles and then applied with the agents, conjugates or microparticles to the tissue. In some embodiments, it may be desired that the conjugates and microparticles penetrate the skin up to but not into the layer of living cells. In some embodiments, it is desired that the agents enter the layer of living cells. Thus, rather than being located on the skin surface, the agents, conjugates or microparticles may be located within the skin surface.
- microparticles which possess both lysine and amine or aldehyde reactive groups. Once the microparticles enter the layer of living cells and are exposed to lysine oxidase, they are likely to crosslink with each other (i.e., covalent bonds may be formed between lysine oxidase products on one microparticle and amines or aldehydes on another). The crosslinked microparticles may then become so large that they are unable to exit the layer of living cells and are thus retained in this layer.
- the lysine oxidase may be endogenous or exogenous.
- the microparticles be applied to the tissue (e.g., the skin) prior to the lysine oxidase.
- the microparticles are preferably small enough in size to do so (e.g., less than 100 ⁇ m).
- the microparticles may be those which degrade following the treatment period. If the microparticles are provided to the skin surface as part of a formulation such as those listed above, it is important that the majority of the active agent does not exit (i.e., leach) from the microparticle and into the formulation prior to contact with the skin. Preferably, the active agent is not substantially soluble in the formulation.
- the agent will exit the microparticle only upon contact with the skin. This may occur if, for example, the active agent is specifically soluble at higher temperatures (such as at the skin surface), or in the bodily secretions at the skin surface.
- the microparticle may be made from substances which are temperature or environment sensitive, so that contact with the skin but not necessarily with the formulation induces their disintegration and the subsequent release of the active agent.
- Thermosensitive polymers in the form of poly (ether-ester) block copolymers are reported by Cha et al., in U.S. Patent 5,702,717.
- the agents, conjugates, and microparticles of the invention may optionally be combined with a pharmaceutically-acceptable carrier to form a pharmaceutical preparation.
- a pharmaceutically-acceptable carrier as used herein means one or more compatible solid or liquid filler, diluents or encapsulating substances which are suitable for administration into a human.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the components of the pharmaceutical compositions also are capable of being commingled with the agents of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy.
- the pharmaceutical preparations of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptably compositions.
- Such preparations may routinely contain salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents.
- the salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
- compositions and pharmaceutical preparations of agents, conjugates or microparticles may be administered in effective amounts.
- An effective amount in general, means that amount necessary to achieve the pu ⁇ ose for which the active agent is applied. The effective amount will depend upon the mode of administration, the particular condition being treated, the severity of the condition, the needs of the patient, and the desired outcome. It will also depend upon, as discussed above, the stage of the condition, the age and physical condition of the subject, frequency of treatment and mode of treatment, the nature of concurrent therapy, if any, and like factors well known to the medical practitioner.
- the amount is that amount necessary to delay the onset of, slow the progression of, halt altogether the onset or progression of, or diagnose a particular condition being treated.
- the effective amount will be that amount necessary to achieve the desired cosmetic result.
- an effective amount will be that amount necessary to achieve suitable protection from the sun as is conventional.
- the lysine oxidase acts on the tissue to convert lysine amines to lysine aldehydes.
- the lysine aldehydes then are available to react (without further exogenous assistance or treatment) with amines and aldehydes which are the reactive groups appended to the agents or microparticles.
- the effect of the addition of lysine oxidase could be examined by tissue section, by dyes, in vitro, etc., but the practical effect can be determined by presence of the agents or microparticles over an extended period of time, reflecting covalent attachment of the agent (or microparticle) to the body tissue (e.g., the skin).
- the extent of attachment will be affected not only by the concentration, amounts, etc. of the lysine oxidase, but also by the concentrations, amounts, surface availabilities (in the case of microparticles), etc. of the reactive groups. Effective amounts, ultimately, will be determined by the combination of these factors together with the parameters described above, such as agent selection, condition being treated, mode of administration and the like. These factors can be manipulated and optimized by those of ordinary skill in the art with no more than routine experimentation.
- the mode of delivery typically will be topical. Other modes of delivery are, nonetheless, appropriate depending on the condition being treated. Aerosols are an example of an appropriate mode of delivery. Generally, doses of active compounds of the present invention would be from about
- a variety of administration routes are available, although topical routes are preferred. The methods of the invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such modes of administration include oral, rectal, topical, nasal or interdermal routes.
- the active agents, the microparticles and the formulations in which they are provided can be in solid, semi-solid or liquid form.
- Solid forms include for example, powders, granules and flakes.
- Semi-solid forms include, for example, gels, creams, gelatins and ointments.
- Formulations for topical administration are known to those of ordinary skill in the art and, in most cases, are commercially available from suppliers such as Paddock Laboratories and Gallipot. Information on topically active and inactive agents, and their commercial suppliers is available from various trade manuals, most particularly, Remington's Pharmaceutical Sciences, United States Pharmacopoeia (USP), National Formulary (NF), Merck Index, Physician's Desk Reference (PDR) and Chemical Abstracts.
- USP United States Pharmacopoeia
- NF National Formulary
- Merck Index Physician's Desk Reference
- PDR Physician's Desk Reference
- Chemical Abstracts The invention also provides kits.
- the kit is a package 10 comprising a housing 12 holding a first container 14, a second container 16 and a third container 18.
- the kits optionally may be comprised of a single container which houses the agent, conjugate, or microparticle compositions described above, either alone, in a pharmaceutically acceptable carrier or in a topically applied formation.
- the kit may alternatively contain more than one container in which case they are provided in a package which houses the containers.
- a second container may be provided which contains lysine oxidase.
- a third container may also be provided which contains, for example, a linking molecule for preparing the surface of the body tissue for application of the agent, conjugate, or microparticle.
- the various containers may also contain cleansers for the skin, catalysts, preservatives, buffers, vehicles, and the like, as is conventional.
- the kit also houses instructions for using the materials according to the invention, particularly for the topical administration of the agents, conjugates, or microparticles.
- the instructions may be provided separately from the containers (e.g., on a sheet of paper enclosed in the kit) or on one of the containers (e.g., text on the outside surface of a container).
- the kit contains lysine oxidase.
- the lysine oxidase may be exogenously added lysine oxidase or may be endogenous lysine oxidase present at the tissue.
- the agent may be a sunscreen agent.
- sunscreen agents include: p-aminobenzoate analogs such as 2-ethylhexyl-4-dimethylaminobenzoate (Padimate O); p-methoxy-2-ethyl-hexyl-cinnamate (Parsol 1789); oxybenzone (benzophenone-3); ethylhexylsalicylate; diphenylacrylate polyisobutylene; alky l- ⁇ , ⁇ -diphenylacry late and ⁇ -cyano- ⁇ , ⁇ -diphenylacrylate;l-(4- aminophenyl)-2-morpholinylethanone; (l-(4-methoxylphenyl)-3-(4-tert-butyl-phenyl)-propan-l-3-dione; methyl anthranilate; octocrylene; Tretinoin ⁇ -hydroxyacid; diphenylacrylate polyisobutylene;
- sunscreen agents include: 3-benzylidene camphor; 4-methylbenzylidene camphor; allantoin PABA benzalphthalide; benzophenone; benzophenone- 1 ; benzophenone-10; benzophenone- 11 ; benzophenone-12; benzophenone-2; benzophenone-3; benzophenone-4; benzophenone-5; benzophenone-6; benzophenone-7; benzophenone- 8; benzophenone-9; benzyl salicylate; benzylidene camphor sulfonic acid; bornelone; bumetrizole; butyl meth oxydibenzoylm ethane; camphor benzalkonium methosulfate; cinoxate; DEA-methoxycinnamate; diisopropyl methyl cinnamate; dimethyl PABA ethyl cetearyldimonium tosylate; drometrizole; ethyl cinnamate
- sunscreen agents include: derivatives of para-amine benzoic acid (PABA); salicylates; cinnamates; benzophenones; camphors;4-aminobenzoic acid; N,N,N- trimethyl-4-(2-oxoborn-3-ylidenemethyl) anilinium methyl sulphate; homosalate (INN); oxybenzone (INN); 2- phenylbenzimidazole-5-sulphonic acid and its potassium, sodium and triethanolamine salts; 3,3'-(l ,4- phenylenedimethylene) bis (7,7-dimethyl-2-oxobicyclo-[2.2.1] hept- 1 -ylmethanesulphonic acid) and its salts; 1- (4-tert-butylphenyl)-3-(4-methoxyphenyl) propane- 1 ,3-dione; alpha-(2-oxoborn-3-ylidene) toluene-4-s
- PABA para-
- the agent may also be a cosmetic agent.
- cosmetic components include: Vitamin C; Alpha -tocopherol (Vit. E analog); Ammonium lauryl Sulfate; Cocamidopropyl Betaine; Lauramide DEA; Cocamide DEA; Methyl paraben; Propyl paraben; Butyl paraben; Salicylic acid; Propylene glycol; EDTA; BHT; BHA; TBHQ; DMDM hydantoin; Imidazolidinyl urea; Potassium sorbate; Sodium Benzoate; phenoxyethanol; Polysorbate 20 and 80; Sodium laurylether sulfate; Oleyl betaine; Tego betaine; Sorbitol; Glycerin monolaurate; Glycerol stearate.
- the agent may also be a coloring agent for coloring hair or skin.
- a coloring agent is one which is able to change the color of skin, hair or nails. Color change may be effected through for example, a lightening or darkening of skin, hair or nails. Examples of coloring agents for hair include: 1,2,4-benzenetriacetate;
- 1,2,4-trihydroxybenzene 1,2,4-trihydroxybenzene; l,3-bis-(2,4-diaminophenoxy)propane; 1,5-naphthalenediol; 1-naphthol; 2,3-naphthalenediol; 2,4-diamino-5-methylphenetol HCl; 2,4-diamino-5-methylphenoxyethanol HCl;
- 2,4-diaminodiphenylamine 2,4-diaminophenol; 2,4-diaminophenol HCl; 2,4-diaminophenoxyethanol HCl;
- 6-amino-o-cresol 6-hydroxyindole; 6-methoxy-2,3-pyridinediamine HCl; 6-nitro-2,5-pyridinediamine;
- N,N-diethyl-m-aminophenol N,N-diethyl-m-aminophenol sulfate; N,N-dimethyl 2,6-pyridinediamine HCl;
- N,N-dimethyl-p-phenylenediamine N,N-dimethyl-p-phenylenediamine sulfate
- N-substituted derivatives and their salts N-substituted derivatives of o-phenylenediamines; methylphenylenediamines, their N-substituted derivatives and their salts; diaminophenols; hydroquinone; alpha- naphthol; lead acetate.
- Coloring agents also include bleaching agents such as ammonium persulfate; hydroquinone and strontium dioxide.
- coloring agents are cosmetic colorants which include: acid red 195; aluminum stearate; anthocyanins; beta vulgaris; beta vulgaris; bismuth oxychloride; bromocresol green; bromothymol blue; calcium stearate; capsanthin/capsorubin caramel; Cl 10006; Cl 10020; Cl 10316; Cl 10316; Cl 11680; Cl 11710; Cl 11725; Cl 11920; Cl 12010; Cl 12085; Cl 12120; Cl 12150; Cl 12370; Cl 12420; Cl 12480; Cl 12490; Cl
- the agent may also be a moisturizing agent.
- a moisturizing agent is an agent which softens and smoothens skin and in some instances hair. Some moisturizing agents are also humectants in that they are able to hold and retain moisture.
- Emollient agents can be moisturing agents. Moisturizing agents can be used soften skin prior to abrasive events such as shaving. In these latter embodiments, the composition of the invention comprising a moisturizing agent can be supplied in a shaving gel or creme.
- moisturizing agents include: proteoglycans and glycosaminoglycans including hyaluronic acid, crosslinked hyaluronic acid, derivatized hyaluronic acid, chondroitin sulfate; mono- and poly-hydroxyl containing chemicals such as glycerin, sorbitol; pyrrolidine carboxylic acid; proteins such as hydrolyzed animal and vegetable protein, collagens, derivatized collagens, elastins; allantoin; polymer skin conditioning agents; polyols such as glycerol; chitosans; derivatized chitosans; and polylysine.
- proteoglycans and glycosaminoglycans including hyaluronic acid, crosslinked hyaluronic acid, derivatized hyaluronic acid, chondroitin sulfate; mono- and poly-hydroxyl containing chemicals such as glycerin, sorbitol; pyr
- moisturizing agents include D,L-panthenol, D-panthenol, vitamin A palmitate, vitamin E acetate, methylsilanetriol mannuronate, natural oils such as tallow oil, macadamia nut oil, borage oil, evening primrose oil, kukui nut oil, rice bran oil, tea tree oil, a medium chain fatty acid ester of glycerol, such as glycerol triheptanoate, glyceryl trioctanoate, glycerol trioctanoate, mineral water, silicones, silicone derivatives; allantoin; dipotassium glycyrrhizinate; stearyl glycyrrhizinate; squalane NF; squalane EX; cetyl ester wax; orange roughy oil; hydrogenated phospholipids; hydrocarbon oils and waxes, such as mineral oil, polyethylene and paraffin; triglyceride esters
- Emollients useful in the invention as moisturizers include: acetamidoethoxybutyl trimonium chloride; acetyl trioctyl citrate; acetylated castor oil; acetylated cetyl hydroxyprolinate; acetylated glycol stearate; acetylated hydrogenated cottonseed glyceride; acetylated hydrogenated lanolin; acetylated hydrogenated lard glyceride; acetylated hydrogenated tallow glyceride; acetylated hydrogenated tallow glycerides; acetylated hydrogenated vegetable glyceride; acetylated lanolin; acetylated lanolin alcohol; acetylated lanolin ricinoleate; acetylated lard glyceride; acetylated palm kernel glycerides; acetylated sucrose diste
- Humectants useful in the invention as moisturizing agents include: 1 ,2,6-hexanetriol; acetamide MEA; aluminum hydroxide; arachidyl glycol; arginine PCA; butoxypropanol; butylene glycol; butyloctanol; capryl glycol; carboxymethyl chitosan succinamide; chitosan PCA; copper acetyl tyrosinate methylsilanol; copper
- PCA copper PCA methylsilanol; cyclomethicone; diglycerin; dimethicone copolyol acetate; dimethicone copolyol adipate; dimethicone copolyol behenate; dimethicone copolyol butyl ether; dimethicone copolyol hydroxystearate; dimethicone copolyol isostearate; dimethicone copolyol laurate; dimethicone copolyol methyl ether; dimethicone copolyol phosphate; dimethicone copolyol stearate; dimethicone copolyolamine; dimethicone silylate; dimethyl imidazolidinone; dimethylsilanol hyaluronate; dipotassium glycyrrhizate; erythritol; ethoxydiglycol; fructose;
- PEG-10 propylene glycol; PEG-100; PEG-12; PEG-135; PEG-14; PEG-150; PEG-16; PEG-18; PEG-180;
- PEG-2 lactamide lactamide; PEG-20; PEG-20 stearate; PEG-200; PEG-240; PEG-25M; PEG-3 stearate; PEG-32; PEG-4;
- PCA PPG-20 methyl glucose ether
- PPG-20 methyl glucose ether distearate PPG-38-buteth-37
- propylene glycol pyridoxine dilaurate
- saccharide isomerate Scharide isomerate
- serica serum albumin
- silk amino acids sodium carboxymethyl chitin; sodium lactate; sodium mannuronate methylsilanol
- sodium PCA sodium PCA
- sodium PCA methylsilanol sodium PG-propyl thiosulfate dimethicone
- sodium polyglutamate soluble collagen; sorbitol; soy sterol; sucrose; sulfated castor oil; TEA-lactate; TEA-PCA; trehalose; tricontanyl PVP; trifluoromethyl Cl-4 alkyl dimethicone; trilactin; urea: xylitol; zea mays; zinc PCA.
- the agent can also be a depilatory agent.
- a depilatory agent is an agent which removes body hair.
- depilatory agents include: alkali sulphides; alkaline earth sulphides; ammonium thioglycolate; ammonium thiolactate; barium sulfide; calcium sulfide: calcium thioglycolate; ethanolamine thioglycolate; glyceryl thioglycolate; isooctyl thioglycolate; lithium sulfide; magnesium sulfide; magnesium thioglycolate; mercaptopropionic acid; potassium sulfide; potassium thioglycolate; sodium sulfide; sodium thioglycolate; strontium sulfide; strontium thioglycolate; thioglycerin; thioglycollic acid and its salts; thiolactic acid; and zinc sulfide.
- a preferred cosmetic agent is any of the known bulking agents which can be added to the hair or nails to provide 'body' and strength.
- Bulking agents are well known to those of ordinary skill in the art.
- Examples of bulking agents generally include cationic surfactant/polymers, fatty alcohols (non-ionic surfactant), waxes or esters, non-ionic polymers (e.g. polyglycols) for thickening, and insoluble silicone.
- the preferred bulking agent is the cationic surfactant, which places a dispersive charge on the hair.
- cationic surfactants include: quaternary ammonium hydroxides, e.g., tetramethylammonium hydroxide, alkyltrimethylammonium hydroxides wherein the alkyl group has from about 8 to 22 carbon atoms, for example octyltrimethylammonium hydroxide, dodecyltrimethy-ammonium hydroxide, hexadecyltrimethylammonium hydroxide, cetyltrimethylammonium hydroxide, octyldimethylbenzylammonium hydroxide, decyldimethyl-benzylammonium hydroxide, stearyldimethylbenzylammonium hydroxide, didodecyldimethylammonium hydroxide, dioctadecyldimethylammonium hydroxide, tallow trimethylammonium hydroxide, cocotrimethylammonium hydroxide, and the corresponding salts thereof, e.g.,
- Additional bulking agents can be solutions of proteins, peptides, and polynucleotides or combinations thereof.
- Particular bulking agents include collagen, keratins, plant structural proteins, silk, fibrin, mucopolysaccharide and elastin.
- Other examples of bulking agents include: polylysine; biotin, panthenol, glycoprotein, and mucopolysaccharide; amodimethicone; acrylates; dimethicone copolymer; di-isobutyl adipate; isododecane; polypropylene glycol, glycerol, disaccharides, urea, dithiothreitol, edta, methyl paraben, propylparaben; polyvinylpyrrolidone and copolymers or derivatives thereof; for example, copolymers with the ethyl or butyl ester of PV A/MA (partially neutralized), copolymers with vinyl a
- Hair conditioning agents are agents which improve the appearance, texture and sheen of hair as well as increasing hair body or suppleness. Usually these compounds facilitate hair styling.
- hair conditioning agents include: Acetamide MEA; Acetamidoethoxybutyl Trimonium Chloride; Acetylated Lanolin; Acetylated Lanolin Alcohol; Acetylmethionyl Methylsilanol Elastinate; Acrylates/Carbamate Copolymer; Alanine; Albumen; Alfalfa (Medicago Sativa) Oil Unsaponifiables; Atmondamidopropalkonium Chloride; Almondamidopropyl Betaine; Aluminum Capryloyl Hydrolyzed Collagen; Aluminum Undecylenoyl Collagen Amino Acids; Amino Bispropyl Dimethicone; Aminopropyl Dimethicone; Aminopropyl Laurylglutamine; Ammoni
- Cocoamphodipropionate Disodium Cystinyl Disuccinate; Disodium Dicarboxyethyl Cocopropylenediamine: Disodium Hydrogenated Tallow Glutamate; Disodium Isostearoamphodiacetate; Disodium Isostearoamphodipropionate; Disodium Laureth-5 Carboxyamphodiacetate; Disodium Lauriminodipropionate; Disodium Lauroamphodiacetate; Disodium Lauroamphodipropionate; Disodium Oleoamphodipropionate; Disodium PPG-2-Isodeceth-7 Carboxyamphodiacetate; Disodium Steariminodipropionate; Disodium Stearoamphodiacetate; Disodium Stearoyl Glutamate; Disodium Tallowamphodiacetate; Disodium Tallowiminodipropionate; Disodium Wheatgermamphodiacetate; Disoyamidoethyl Hydroxyeth
- Bisisostearamidopropyldimonium Chloride Hydroxypropyl Bisoleyldimonium Chloride; Hydroxypropyl Bisstearyidimonium Chloride; Hydroxypropyldimethicone; Hydroxypropyl Guar Hydroxypropyltrimonium Chloride; Hydroxypropyltrimonium Gelatin; Hydroxypropyitrimonium Honey; Hydroxypropyltrimonium Hydrolyzed Casein; Hydroxypropyltrimonium Hydrolyzed Collagen; Hydroxypropyltrimonium Hydrolyzed Keratin; Hydroxypropyltrimonium Hydrolyzed Rice Bran Protein; Hydroxypropyltrimonium Hydrolyzed Silk; Hydroxypropyltrimonium Hydrolyzed Soy Protein; Hydroxypropyltrimonium Hydrolyzed Vegetable Protein; Hydroxypropyltrimonium Hydrolyzed Wheat Protein; Hydroxystearamidopropyl Trimonium Chloride; Hydroxystearamidopropyl Trimonium
- Palmitamidopropylamine Oxide Palmitamidopropyl Betaine; Palmitamine Oxide; Palmitoyl Collagen Amino Acids; Palmitoyl Glycine; Palmitoyl Hydrolyzed Collagen; Palmitoyl Hydrolyzed Milk Protein; Palmitoyl Hydrolyzed Wheat Protein; Palmitoyl Keratin Amino Acids; Palmitoyl Pea Amino Acids; Palmitoyl PG- Trimonium Chloride; Palmitoyl Quinoa Amino Acids; Palmitoyl Silk Amino Acids; Palm Kernelamidopropyl Betaine; Pancreatin; Pantethine; Panthenol; Panthenyl Ethyl Ether; Panthenyl Ethyl Ether Acetate; Panthenyl
- Antistatic agents can sometimes also be used as hair conditioning agents.
- Antistatic agents are agents reduce static electricity by neutralizing electrical charge on a surface.
- Antistatic agents include: acetamide MEA; acetamidoethoxybutyl trimonium chloride; acetamidopropyl trimonium chloride; acetum; acetylated lanolin; acetylated lanolin alcohol; acetylated lanolin ricinoleate; acetylmethionyl methylsilanol elastinate; acrylamide/sodium acrylate copolymer; acrylamides copolymer; acrylates/ammonium methacrylate copolymer acrylates/pvp copolymer; acrylates copolymer; adipic acid/dimethylaminohydroxypropyl diethylenetriamine copolymer; adipic acid epoxypropyl diethylenetriamine copolymer; alanine; allanto
- PEG-5 stearyl ammonium chloride PEG-5 stearyl ammonium lactate; PEG-5 tall oil sterol ether; PEG-5 tallow benzonium chloride; PEG-50 stearamine; PEG-8 palmitoyl methyl diethonium methosulfate; petrolatum;
- PVP/dimethylaminoethylmethacrylate copolymer PVP/eicosene copolymer; PVP/hexadecene copolymer; PVP/VA/itaconic acid copolymer; PVP/V A/vinyl propionate copolymer; PVP/va copolymer; pyridoxine; pyridoxine dicaprylate; pyridoxine dilaurate; pyridoxine dioctenoate; pyridoxine dipalmitate; pyridoxine HCl; pyridoxine tripalmitate; quaternium- 1 ; quaternium- 14; quaternium- 16; quaternium- 18; quaternium- 18 methosulfate; quaternium-22; quaternium-24; quaternium-26; quaternium-27; quaternium-30; quaternium-33; quaternium-43; quaternium-45;
- cationic and amphoteric fatty acids such as polyquatemium compounds are useful as hair conditioners or fixatives.
- cationic amino and quaternary ammonium monomers include, for example, vinyl compounds substituted with dialkyl aminoalkyl acrylate, dialkylamino alkylmethacrylate, monoalkylaminoalkyl acrylate, monoalkylaminoalkyl methacrylate, trialkyl methacryloxyalkyl ammonium salt, trialkyl acryloxyalkyl ammonium salt, diallyl quaternary ammonium salts, and vinyl quaternary ammonium monomers having cyclic cationic nitrogen-containing rings such as pyridinium, imidazolium, and quaternized pyrrolidine, e.g., alkyl vinyl imidazolium, alkyl vinyl pyridinium, and alkyl vinyl pyrrolidine salts.
- the alkyl portions of these, monomers are preferably lower alkyls such as
- octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer a polymer of N-tert-octyl acrylamide, methyl methacrylate, hydroxypropyl methacrylate, acrylic acid and t-butyl aminoethyl methacrylate.
- cationic conditioning compounds include quaternary nitrogen derivatives of cellulose ethers, homopolymers of dimethyldiallyl-ammonium chloride, copolymers of acrylamide and dimethyldiallylammonium chloride, homopolymers or copolymers derived from acrylic acid or methacrylic acid containing cationic nitrogen functional groups attached to the polymer via ester or amide linkages, polycondensation products of N,N'-bis-(2,3-epoxypropyl)-piperazine or of piperazine-bis-acrylamide and piperazine, poly-(dimethylbutenylammonium chloride)- ⁇ , ⁇ -bis-(triethanol-ammonium) chloride.
- the agent can also be a hair fixative as described above.
- Hair fixatives are agents which impart hair- holding or style-retention properties to hair.
- Film formers such as gums and polymeric substances, can also be used as hair fixatives.
- hair fixative agents including some film formers which are suitable hair fixatives include: Acrylamide/Ammonium Acrylate Copolymer; Acrylamides/DMAPA Acrylates/Wethoxy PEG Methacrylate Copolymer; Acrylamidopropyltrimonium Chloride/Acrylamide Copolymer; Acrylamidopropyltrimonium Chloride/Acrylates Copolymer; Acrylates/Acetoacetoxyethyl Methacrylate Copolymer; Acrylates/Acrylamide Copolymer; Acrylates/Ammonium Methacrylate Copolymer; Acrylates Copolymer; Acrylates/Octylacrylamide Copolymer; Acrylates/PVP Copolymer
- Other compounds which are useful as hair fixatives include shellac, polyvinylpyrrolidone-ethyl methacrylate-methacrylic acid tarpolymer, vinyl acetate-crotonic acid copolymer, vinyl acetate-crotonic acid-vinyl neodeconate ta ⁇ olymer, poly(vinylpyrrolidone-ethylmethacrylate) methacrylic acid copolymer, vinyl methyl ether-maleic anhydride copolymer, octylacrylamide-acrylate-butylaminoethyl-methacrylate copolymer, and poly(vinylpyrrolidone-dimethylaminoethyl-methacrylate) copolymer and derivatives; thioglycollic acid and its salts and esters; potassium or sodium hydroxide; lithium hydroxide; calcium hydroxide; quinine and its salts; resorcinol; l,3-bis
- anti-foaming agents which are useful as bulking agents include: bisphenylhexamethicone; dimethicone; dimethiconol; hexamethyldisiloxane; hexyl alcohol; isopropyl alcohol; petroleum distillates; phenethyl disiloxane; phenyl trimethicone; polysilicone-7; propyl alcohol; silica dimethyl silylate; silica silylate; tetramethyl decynediol; trimethylsiloxysilicate.
- the agent also can be a tissue sealant. Tissue sealants are those used in wound healing to mechanically seal wounds.
- tissue sealants are composed typically of fibrinogen, collagen, hyaluronic acid, synthetic peptides and the like. They also can be polylysines, or polymers of both glutamine and lysine, corneocyte proteins and the like.
- the agents also can be insect repellants. A widely used insect repellant is N-N-diethyl-3- methylbenzamide. Pheromones are also useful as insect repellants.
- the agent also may be cultured cells and cultured body tissues used for wound healing, cartilage replacement, comeal replacements and other like surgical procedures.
- the agent can also be a film forming agent.
- a film forming agent is an agent which produces a continuous film on skin, hair or nails upon application. Film forming agents are useful in wound healing or in some cases as hair fixatives, as described above. Examples of film forming agents include: acetyl tributyl citrate; acetyl triethyl citrate; acetyl trioctyl citrate; acrylamide/sodium acrylate copolymer; acrylamides/acrylates/DMAPA/methoxy PEG methacrylate copolymer; acrylamides copolymer; acrylamidopropyltrimonium chloride/acrylates copolymer; acrylates/acetoacetoxyethyl methacrylate copolymer; acrylates/acrylamide copolymer; acrylates/ammonium methacrylate copolymer; acrylates/C 10-30 alkyl acrylate crosspolymer; acrylates/diacetoneacryl
- the agent can also be an anti-nerve gas agent.
- An anti-nerve gas agent is an agent which counteracts the effects of a nerve gas agent.
- anti-nerve gas agents include: organophosphate hydrolases such as phosphotriesterase; pyridostigmine, physostigmine, eptastigmine, pralidoxime-2-chloride (2-PAM); potassium 2,3-butadion monoximate; potassium permanganate; sodium phenolate or sodium cresolate; chlorinated lime and magnesium oxide; chloramines; bentonite; and a mixture of atropine and PAM.
- the agent can also be a vitamin including vitamin A,vitamin B, vitamin C, vitamin D, vitamin E, and their provitamin counte ⁇ arts.
- the agent may be a pharmaceutical agent.
- Examples of categories of pharmaceutical agents include: analgesic; amino acid; antagonist; anti-acne agent; anti-allergic; anti-asthmatic; antibacterial; anticholinergic; antifungal; antiglaucoma agent; antihistamine; anti-infective; anti-infective, topical; anti-inflammatory; antikeratinizing agent; antimicrobial; antimycotic; antineoplastic, antineutropenic; antiproliferative; antipruritic; antiseborrheic; carbonic anhydrase inhibitor; cholinergic; cholinergic agonist; diagnostic aids; ectoparasiticide; fluorescent agent; glucocorticoid; hair growth stimulant; histamine H2 receptor antagonists; immunizing agent; immunomodulator; immunoregulator; immunostimulant; immunosuppressant; keratolytic; mucosal protective agent; radio; wound healing agent.
- Analgesic Acetaminophen; Alfentanil Hydrochloride;
- Methadone Hydrochloride Methadyl Acetate; Methopholine; Methotrimeprazine; Metkephamid Acetate;
- Pentazocine Pentazocine Hydrochloride
- Pentazocine Lactate Pentazocine Lactate
- Phenazopyridine Hydrochloride Phenyramidol
- Prodilidine Hydrochloride Profadol Hydrochloride; Propiram Fumarate; Propoxyphene Hydrochloride; Propoxyphene Napsylate; Proxazole ; Proxazole Citrate ; Proxo ⁇ han Tartrate; Pyrroliphene Hydrochloride;
- Tazadolene Succinate Tebufelone ; Tetrydamine ; Tifurac Sodium; Tilidine Hydrochloride; Tiopinac;
- Tonazocine Mesylate Tramadol Hydrochloride; Trefentanil Hydrochloride; Trolamine; Veradoline Hydrochloride; Verilopam Hydrochloride; Volazocine; Xo ⁇ hanol Mesylate; Xylazine Hydrochloride;
- Zenazocine Mesylate Zomepirac Sodium ; Zucapsaicin.
- Antiacne Adapalene; Erythromycin Salnacedin; Inocoterone Acetate.
- Antiallergic Amlexanox; Astemizole; Azelastine Hydrochloride; Eclazolast; Minocromil; Nedocromil;
- Thiazinamium Chloride Tiacrilast; Tiacrilast Sodium; Tiprinast Meglumine; Tixanox.
- Antiasthmatic Ablukast; Ablukast Sodium; Azelastine Hydrochloride; Bunaprolast; Cinalukast; Cromitrile
- Tiaramide Hydrochloride Tibenelast Sodium; Tomelukast; Tranilast; Verlukast; Verofylline; Zarirlukast.
- Antibacterial Acedapsone; Acetosulfone Sodium; Alamecin; Alexidine; Amdinocillin; Amdinocillin Pivoxil;
- Biphenamine Hydrochloride Bispyrithione Magsulfex; Butikacin; Butirosin Sulfate; Capreomycin Sulfate; Carbadox; Carbenicillin Disodium; Carbenicillin Indanyl Sodium; Carbenicillin Phenyl Sodium; Carbenicillin
- Cefepime Cefepime Hydrochloride; Cefetecol; Cefixime; Cefmenoxime Hydrochloride; Cefmetazole;
- Cefpimizole Cefpimizole Sodium; Cefpiramide; Cefpiramide Sodium; Cefpirome Sulfate; Cefpodoxime
- Ciprofloxacin Ciprofloxacin Hydrochloride
- Cirolemycin Cirolemycin
- Clarithromycin Clinafloxacin Hydrochloride
- Demeclocycline Demeclocycline Hydrochloride
- Demecycline Denofungin
- Diaveridine Dicloxacillin
- Dicloxacillin Sodium Dihydrostreptomycin Sulfate; Dipyrithione; Dirithromycin; Doxycycline; Doxycycline
- Erythromycin Gluceptate Erythromycin Lactobionate; Erythromycin Propionate; Erythromycin Stearate;
- Ethambutol Hydrochloride Ethionamide; Fleroxacin; Floxacillin; Fludalanine; Flumequine; Fosfomycin;
- Fosfomycin Tromethamine Fumoxicillin; Furazolium Chloride; Furazolium Tartrate; Fusidate Sodium; Fusidic
- Gentamicin Sulfate Gloximonam; Gramicidin; Haloprogin; Hetacillin; Hetacillin Potassium; Hexedine; Ibafloxacin; Imipenem; Isoconazole; Isepamicin; Isoniazid; Josamycin; Kanamycin Sulfate; Kitasamycin;
- Lomefloxacin Lomefloxacin Hydrochloride; Lomefloxacin Mesylate; Loracarbef; Mafenide; Meclocycline;
- Meclocycline Sulfosalicylate Megalomicin Potassium Phosphate; Mequidox; Meropenem; Methacycline; Methacycline Hydrochloride; Methenamine; Methenamine Hippurate; Methenamine Mandelate; Methicillin
- Neomycin Nafcillin Sodium; Nalidixate Sodium; Nalidixic Acid; Natamycin; Nebramycin; Neomycin Palmitate; Neomycin
- Neomycin Undecylenate Netilmicin Sulfate; Neutramycin; Nifuradene; Nifuraldezone; Nifuratel ; Nifuratrone; Nifurdazil; Nifurimide; Nifurpirinol; Nifurquinazol; Nifurthiazole; Nitrocycline; Nitrofurantoin;
- Temafloxacin Hydrochloride Temocillin; Tetracycline; Tetracycline Hydrochloride ; Tetracycline Phosphate Complex; Tetroxoprim; Thiamphenicol; Thiphencillin Potassium; Ticarcillin Cresyl Sodium; Ticarcillin
- Anticholinergic Alverinc Citrate; Anisotropine Methylbromide; Atropine; Atropine Oxide Hydrochloride; Atropine Sulfate; Belladonna; Benapryzine Hydrochloride; Benzetimide Hydrochloride; Benzilonium Bromide;
- Biperiden Biperiden Hydrochloride
- Biperiden Lactate Clidinium Bromide
- Cyclopentolate Hydrochloride
- Elucaine Ethybenztropine
- Eucatropine Hydrochloride Glycopyrrolate
- Heteronium Bromide Homatropine
- Methylsulfate Tiquinamide Hydrochloride; Tofenacin Hydrochloride; Toquizine; Triampyzine Sulfate; Trihexyphenidyl Hydrochloride; Tropicamide.
- Antifungal Acrisorcin; Ambmticin; Amphotericin B; Azaconazole; Azaserine; Basifungin; Bifonazole;
- Biphenamine Hydrochloride Bispyrithione Magsulfex ; Butoconazole Nitrate; Calcium Undecylenate;
- Clotrimazole Cuprimyxin; Denofungin ; Dipyrithione; Doconazole; Econazole; Econazole Nitrate; Enilconazole; Ethonam Nitrate; Fenticonazole Nitrate; Filipin; Fluconazole; Flucytosine; Fungimycin;
- Griseofiilvin Hamycin; Isoconazole ; Itraconazole; Kalafungin; Ketoconazole; Lomofungin; Lydimycin;
- Mepartricin Mepartricin ; Miconazole; Miconazole Nitrate; Monensin ; Monensin Sodium ; Naftif e Hydrochloride;
- Neomycin Undecylenate Nifuratel ; Nifurmerone; Nitralamine Hydrochloride; Nystatin; Octanoic Acid;
- Ticlatone Tioconazole; Tolciclate; Tolindate; Tolnaftate; Triacetin; Triafungin; Undecylenic Acid;
- Antiglaucoma agent Alprenoxime Hydrochloride ; Colforsin; Dapiprazole Hydrochloride ; Dipivefrin Hydrochloride ; Naboctate Hydrochloride ; Piloca ⁇ ine; Pimabine.
- Antihistaminic Acrivastine; Antazoline Phosphate; Astemizole ; Azatadine Maleate; Barmastine;
- Difloxacin Hydrochloride Lauryl Isoquinolinium Bromide; Moxalactam Disodium; Omidazole;
- Pentisomicin Sarafloxacin Hydrochloride
- Protease inhibitors of HIV and other retroviruses Integrase Inhibitors of HIV and other retroviruses
- Cefaclor Ceclor
- Acyclovir Zaovirax
- Norfloxacin Noroxin
- Cefoxitin
- Amcinafide Amfenac Sodium; Amiprilose Hydrochloride; Anakinra; Anirolac ; Anitrazafen; Apazone;
- Clopirac Cloticasone Propionate; Cormethasone Acetate; Cortodoxone; Deflazacort; Desonide; Desoximetasone; Dexamethasone Dipropionate; Diclofenac Potassium; Diclofenac Sodium; Diflorasone
- Fenclofenac Fenclorac; Fendosal; Fenpipalone; Fentiazac; Flazalone; Fluazacort; Flufenamic Acid; Flumizole;
- Orgotein O ⁇ anoxin; Oxaprozin; Oxyphenbutazone; Paranyline Hydrochloride; Pentosan Polysulfate Sodium;
- Prednazate Prifelone; Prodolic Acid; Proquazone; Proxazole; Proxazole Citrate ; Rimexolone; Romazarit ;
- Salcolex Salcolex ; Salnacedin; Salsalate ; Sanguinarium Chloride ; Seclazone ; Sermetacin; Sudoxicam; Sulindac; Suprofen; Talmetacin; Talniflumate ; Talosalate ; Tebufelone ; Tenidap; Tenidap Sodium; Tenoxicam; Tesicam;
- Tesimide Tetrydamine ; Tiopinac; Tixocortol Pivalate; Tolmetin; Tolmetin Sodium; Triclonide; Triflumidate;
- Antikeratinizing agent Doretinel; Linarotene; Pelretin.
- AntimicrobiakAztreonam Chlorhexidine Gluconate; Imidurea; Lycetamine; Nibroxane; Pirazmonam Sodium; Propionic Acid ; Pyrithione Sodium; Sanguinarium Chloride ; Tigemonam Dicholine.
- Antimvcotic Amorolfine.
- Antineoplastic Acivicin; Aclarubicin; Acodazole Hydrochloride; Acronine; Adozelesin; Aldesleukin;
- Cyclophosphamide Cytarabine ; dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine;
- Dexormaplatin Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorabicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate;
- Eflornithine Hydrochloride Elsamitrucin; Enloplatin; Enpromate; Epipropidine; Epirubicin Hydrochloride;
- Gemcitabine Hydrochloride Gold Au 198 ; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofosine;
- Interferon Alfa-2a Interferon Alfa-2b ; Interferon Alfa-nl; Interferon Alfa-n3; Interferon Beta-I a; Interferon
- Mitocromin Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride;
- Pentamustine Peplomycin Sulfate; Perfosfamide; Pipobroman; Piposulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin ; Prednimustine; Procarbazine Hydrochloride;
- Puromycin Puromycin Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safingol ; Safingol Hydrochloride;
- Vindesine Vindesine; Vindesine Sulfate; Vinepidine Sulfate; Vinglycinate Sulfate; Vinleursine Sulfate; Vinorelbine
- anti-neoplastic compounds include: 20-epi-l,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing mo ⁇ hogenetic protein-1 ; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin
- Tricyclic anti-depressant drugs e.g., imipramine, desipramine, amitryptyline, clomipramine, trimipramine, doxepin, nortriptyline, protriptyline, amoxapine and maprotiline
- non-tricyclic anti-depressant drugs e.g., sertraline, trazodone and citalopram
- Ca ++ antagonists e.g., verapamil, nifedipine, nitrendipine and caroverine
- Calmodulin inhibitors e.g., prenylamine, trifluoroperazine and clomipramine
- Amphotericin B Triparanol analogues (e.g., tamoxifen); antiarrhythmic drugs (e.g., quinidine); antihypertensive drugs (e.g., rese ⁇ ine); Thiol depleters (e.g., buthionine and sulfoximine) and Multiple Drug Resistance reducing agents such as Cremaphor EL.
- the compounds of the invention also can be administered with cytokines such as granulocyte colony stimulating factor.
- Antineutropenic Filgrastim; Lenograstim; Molgramostim; Regramostim; Sargramostim.
- Antiproliferative agent Piritrexim Isethionate.
- Antiprotozoal Amodiaquine; Azanidazole; Bamnidazole; Camidazole; Chlortetracycline Bisulfate;
- Chlortetracycline Hydrochloride Flubendazole; Flunidazole; Halofuginone Hydrobromide; Imidocarb Hydrochloride; Ipronidazole; Metronidazole; Misonidazole; Moxnidazole; Nitarsone; Partricin; Puromycin;
- Antipruritic Cyproheptadine Hydrochloride ; Methdilazine; Methdilazine Hydrochloride; Trimeprazine Tartrate.
- Antipsoriatic Acitretin; Anthralin; Azaribine; Calcipotriene; Cycloheximide; Enazadrem Phosphate; Etretinate;
- Echothiophate Iodide Isoflurophate; Methacholine Chloride; Neostigmine Bromide; Neostigmine Methylsulfate; Physostigmine; Physostig ine Salicylate; Physostigmine Sulfate; Piloca ⁇ ine ; Piloca ⁇ ine Hydrochloride;
- Diagnostic aid Aminohippurate Sodium; Anazolene Sodium; Arclofenin; Arginine ; Bentiromide;
- Diatrizoic Acid Diphtheria Toxin for Schick Test; Disofenin; Edrophonium Chloride; Ethiodized Oil; Etifenin;
- Impromidine Hydrochloride Indigotindisulfonate Sodium; Indocyanine Green ; lobenguane Sulfate I 123; lobenzamic Acid; locarmate Meglumine; locarmic Acid; locetamic Acid; lodamide; lodamide Megiumine;
- Iodipamide Meglumine Iodixanol; Iodoxamate Meglumine; Iodoxamic Acid; Ioglicic Acid; loglucol;
- Ioglucomide Ioglycamic Acid; Iogulamide; Iohexol; Iomeprol; Iopamidol; lopanoic Acid; Iopentol;
- Iophendylate Iprofenin; Iopronic Acid; Ioprocemic Acid; Iopydol; lopydone; Iosefamic Acid; Ioseric Acid;
- Ioxilan Ioxotrizoic Acid
- Ipodate Calcium Ipodate Sodium
- Isosulfan Blue Leukocyte Typing Serum
- Ectoparasiticide Nifluridide; Permethrin.
- Glucocorticoid Amcinonide; Beclomethasone Dipropionate; Betamethasone; Betamethasone Acetate;
- Betamethasone Benzoate Betamethasone Dipropionate
- Betamethasone Sodium Phosphate Betamethasone
- Acetonide Dexamethasone; Dexamethasone Sodium Phosphate; Diflucortolone; Diflucortolone Pivalate;
- Flucloronide Flumethasone; Flumethasone Pivalate; Flunisolide; Fluocinolone Acetonide; Fluocinonide;
- Fluocortolone Fluocortolone Caproate; Fluorometholone; Fluperolone Acetate; Fluprednisolone;
- Methylprednisolone Sodium Phosphate; Methylprednisolone Sodium Succinate; Nivazol; Paramethasone
- Prednicarbate Prednisolone
- Prednisolone Acetate
- Prednisolone Hemisuccinate Prednisolone Sodium
- Triamcinolone Diacetate Triamcinolone Hexacetonide.
- Hair growth stimulant Minoxidil .
- Histamine H2 receptor antagonists Ranitidine (Zantac); Famotidine (Pepcid); Cimetidine (Tagamet); Nizatidine
- Immunizing agent Antirabies Serum; Antivenin (Latrodectus mactans); Antivenin (Micm s Fulvius);
- Antivenin Polyvalent; BCG Vaccine; Botulism Antitoxin; Cholera Vaccine; Diphtheria Antitoxin;
- Diphtheria Toxoid Diphtheria Toxoid
- Diphtheria Toxoid Adsorbed Globulin, Immune
- Hepatitis B Immune Globulin Hepatitis B
- Virus Vaccine Inactivated Influenza Vims Vaccine; Measles Virus Vaccine Live; Meningococcal Polysaccharide Vaccine Group A; Meningococcal Polysaccharide Vaccine Group C; Mumps Virus Vaccine
- Tetanus Toxoid Tetanus Toxoid Adsorbed; Typhoid Vaccine; Yellow Fever vaccine; Vaccinia Immune Globulin; Varicella-Zoster Immune Globulin.
- Immunomodulator Dimepranol Acedoben; Imiquimod; Interferon Beta-lb; Lisofylline; Mycophenolate Mofetil;
- Immunoregulator Azarole; Fanetizole Mesylate; Frentizole; Oxamisole Hydrochloride; Ristianol Phosphate;
- Thymopentin Tilomisole.
- rmmunostimulant Loxoribine ; Teceleukin.
- Immunosuppressant Azathioprine; Azathioprine Sodium; Cyclosporine; Daltroban; Gusperimus
- Trihydrochloride Trihydrochloride; Sirolimus; Tacrolimus.
- Mucolytic Acetylcysteine; Carbocysteine; Domiodol.
- Radioactive agent Fibrinogen 1 125 ; Fludeoxyglucose F 18 ; Fluorodopa F 18 ; Insulin I 125; Insulin I 131 ;
- lofetamine Hydrochloride I 123 lomethin I 125 ; lomethin 1 131 ; Iothalamate Sodium I 125 ; Iothalamate
- Wound healing agent Ersofermin.
- Example 1 Durable suntan preparation and kit.
- a kit for producing a durable sunscreen.
- the kit includes three reservoirs
- a distilled H 2 O solution a lysine oxidase stock (may be lyophilized)
- a conjugate of a low molecular weight sunscreen agent and a linking agent The three solutions are mixed, as is conventional with such dispensing cans, as they are being applied onto tissue such as skin. The mixture is uniformly spread on the skin and allowed to remain for a sufficient period of time to permit crosslinking. The excess solution is removed by washing.
- Example 2 Durable topical antifungal preparation and kit.
- a kit for producing durable antifungal protection.
- the kit includes three reservoirs (a distilled H 2 O solution, a lysine oxidase stock (may be lyophilized), and a conjugate of an antifungal agent and a linking agent.
- the three solutions are mixed, as is conventional with such dispensing cans, as they are being applied onto tissue such as skin. The mixture is spread and so on as described in Example 1.
- Example 3 Long-term protective preparation for anticholinesterase nerve gas and kit.
- a kit for providing long-term protection from anticholinesterase nerve gas includes four reservoirs (a distilled H O solution, a lysine oxidase stock (may be lyophilized), polylysine coupled to avidin, and recombinant cholinesterase coupled to biotin (e.g., by reaction in the presence of N.N. succinimide).
- the polylysine coupled to avidin is applied to the surface of the skin in the presence of lysine oxidase. After the avidin is coupled to the skin via the polylysine, then the recombinant cholinesterase coupled to biotin is added to bind the biotin to the avidin, thereby coupling the cholinesterase to the skin.
- Example 4 A mousse for thickening hair.
- a dispensing package with three reservoirs (a distilled H O solution, a lysine oxidase stock and a hair bulking or thickening agent such as a mucopolysaccharide linked to polylysine) is provided.
- the three solutions are mixed, as is conventional with such dispensing cans, as they are being applied onto tissue such as hair.
- the mousse can be combed through the hair, left on the hair for a sufficient period of time to permit crosslinking, and then rinsed.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Nanotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Cosmetics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00950656A EP1202706A1 (en) | 1999-07-22 | 2000-07-24 | Lysine oxidase linkage of agents to tissue |
AU63730/00A AU6373000A (en) | 1999-07-22 | 2000-07-24 | Lysine oxidase linkage of agents to tissue |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35998799A | 1999-07-22 | 1999-07-22 | |
US09/359,987 | 1999-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001007009A1 true WO2001007009A1 (en) | 2001-02-01 |
Family
ID=23416138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/020211 WO2001007009A1 (en) | 1999-07-22 | 2000-07-24 | Lysine oxidase linkage of agents to tissue |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1202706A1 (en) |
AU (1) | AU6373000A (en) |
WO (1) | WO2001007009A1 (en) |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001089576A2 (en) * | 2000-05-23 | 2001-11-29 | Andreas Kubin | Preparation hypericin bonded with poly-n-vinylamides |
WO2002007707A2 (en) * | 2000-07-21 | 2002-01-31 | Pericor Science, Inc. | Linkage of agents using microparticles |
WO2002072061A2 (en) * | 2001-03-07 | 2002-09-19 | The Procter & Gamble Company | Topical composition comprising an aldehyde or ketone-based cosmetic bonding agent |
US6511957B1 (en) | 1993-02-19 | 2003-01-28 | Howard Green | Compositions containing corneocyte proteins |
US6565865B2 (en) | 2001-03-07 | 2003-05-20 | The Procter & Gamble Company | Topical composition comprising a three membered cyclic compound-based cosmetic bonding agent |
FR2833486A1 (en) * | 2001-12-18 | 2003-06-20 | Oreal | Cosmetic composition especially useful for hair treatment comprises a non silicone polymer with at least two functional groups |
FR2834209A1 (en) * | 2001-12-31 | 2003-07-04 | Oreal | COSMETIC COMPOSITIONS COMPRISING A COSMETIC ACTIVE AGENT AND AN EXOGENOUS HAIR LIGAND-RECEPTOR SYSTEM AND METHOD FOR TREATING HAIR USING THE SAME |
US6589542B2 (en) | 2001-03-07 | 2003-07-08 | The Procter & Gamble Company | Topical composition comprising a functionally alkylating cosmetic bonding agent |
US6607737B2 (en) | 2001-05-30 | 2003-08-19 | The Procter & Gamble Company | Topical composition comprising an activated, trans-structured cosmetic bonding agent |
US6613341B2 (en) | 2001-05-30 | 2003-09-02 | The Procter & Gamble Company | Topical composition comprising a substituted cosmetic bonding agent |
FR2838640A1 (en) * | 2002-04-19 | 2003-10-24 | Oreal | A method of cosmetic treatment of hair by application of a biotin derivative and a complexing agent where either or both are bonded to a group covalently bonding to hair and either or both to a cosmetically active group |
US6645512B2 (en) | 2001-03-07 | 2003-11-11 | The Procter & Gamble Company | Topical composition comprising a functionally acylating cosmetic bonding agent |
FR2844712A1 (en) * | 2002-09-24 | 2004-03-26 | Oreal | Cosmetic composition, especially for hair treatment, comprises a compound and a complexing agent capable of forming a complex with the compound |
US6812211B2 (en) | 2002-03-19 | 2004-11-02 | Michael Andrew Slivka | Method for nonsurgical treatment of the intervertebral disc and kit therefor |
WO2005067980A2 (en) * | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
US7220405B2 (en) | 2003-09-08 | 2007-05-22 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
WO2007117564A2 (en) | 2006-04-06 | 2007-10-18 | E. I. Du Pont De Nemours And Company | Clay-binding peptides and methods of use |
US7285264B2 (en) | 2003-09-08 | 2007-10-23 | E.I. Du Pont De Nemours And Company | Peptide-based body surface coloring reagents |
US7585495B2 (en) | 2003-09-08 | 2009-09-08 | E. I. Du Pont De Nemours And Company | Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom |
US7632919B2 (en) | 2005-12-15 | 2009-12-15 | E.I. Du Pont De Nemours And Company | Polystyrene binding peptides and methods of use |
US7700716B2 (en) | 2005-12-15 | 2010-04-20 | E. I. Du Pont De Nemours And Company | Polytetrafluoroethylene binding peptides and methods of use |
US7709601B2 (en) | 2005-12-15 | 2010-05-04 | E. I. Du Pont De Nemours And Company | Nylon binding peptides and methods of use |
US7736633B2 (en) | 2005-09-28 | 2010-06-15 | E.I. Du Pont De Nemours And Company | Method for enhancing effects of colorants and conditioners |
WO2010080424A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
WO2010080418A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Iron oxide-binding peptides |
US7807141B2 (en) | 2003-09-08 | 2010-10-05 | E.I. Du Pont De Nemours And Company | Peptide-based oral care surface reagents for personal care |
WO2010114638A1 (en) | 2009-03-30 | 2010-10-07 | E. I. Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
US7858581B2 (en) | 2005-12-15 | 2010-12-28 | E. I. Du Pont De Nemours And Company | PMMA binding peptides and methods of use |
US7906617B2 (en) | 2005-12-15 | 2011-03-15 | E. I. Du Pont De Nemours And Company | Polyethylene binding peptides and methods of use |
US7928076B2 (en) | 2005-12-15 | 2011-04-19 | E. I. Du Pont De Nemours And Company | Polypropylene binding peptides and methods of use |
EP2374465A1 (en) | 2003-09-08 | 2011-10-12 | E. I. du Pont de Nemours and Company | Peptide-based conditioners and colorants for hair, skin and nails |
US8263056B2 (en) | 2007-09-14 | 2012-09-11 | E I Du Pont De Nemours And Company | Dyed-hair-binding peptides and peptide-based hair reagents for personal care |
US8388991B2 (en) | 2009-05-01 | 2013-03-05 | Chattem, Inc. | Moisturizing antimicrobial composition |
EP2633887A1 (en) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Novel agent combination for efficient anti-wrinkle effect |
US8652455B2 (en) | 2010-12-20 | 2014-02-18 | E I Du Pont De Nemours And Company | Targeted perhydrolases |
US8663616B2 (en) | 2010-12-20 | 2014-03-04 | E I Du Pont De Nemours And Company | Enzymatic peracid generation for use in oral care products |
EP2516002B1 (en) * | 2009-12-21 | 2014-04-23 | Colgate-Palmolive Company | Composition for treating and/or preventing conditions caused by microorganisms using an oral light device |
WO2014085421A1 (en) * | 2012-11-28 | 2014-06-05 | Zarzatech, Inc. | Treatment of skin or mucosal pathology |
WO2018112187A1 (en) | 2016-12-16 | 2018-06-21 | E. I. Du Pont De Nemours And Company | Amphiphilic polysaccharide derivatives and compositions comprising same |
WO2019164670A1 (en) | 2018-02-26 | 2019-08-29 | Danisco Us Inc | Compositions for providing skin care benefits and methods of use |
WO2019246228A1 (en) | 2018-06-20 | 2019-12-26 | Dupont Industrial Biosciences Usa, Llc | Polysaccharide derivatives and compositions comprising same |
WO2020131711A1 (en) | 2018-12-17 | 2020-06-25 | Dupont Industrial Biosciences Usa, Llc | Polysaccharide derivatives and compositions comprising same |
CN111956517A (en) * | 2020-09-20 | 2020-11-20 | 陈洁兴 | Facial cleanser and preparation method thereof |
WO2021155118A1 (en) | 2020-01-31 | 2021-08-05 | Dupont Us Holding, Llc | Compositions and methods for microbial treatment of skin disorders |
WO2021252575A1 (en) | 2020-06-10 | 2021-12-16 | Nutrition & Biosciences USA 4, Inc. | Poly alpha-1,6-glucan esters and compositions comprising same |
WO2021252569A1 (en) | 2020-06-10 | 2021-12-16 | Nutrition & Biosciences USA 4, Inc. | Poly alpha-1,6-glucan derivatives and compositions comprising same |
WO2021257786A1 (en) | 2020-06-18 | 2021-12-23 | Nutrition & Biosciences USA 4, Inc. | Cationic poly alpha-1,6-glucan ethers and compositions comprising same |
WO2022119895A1 (en) | 2020-12-01 | 2022-06-09 | Dupont Us Holding, Llc | Methods and compositions for microbial treatment of skin disorders |
WO2023278146A1 (en) | 2021-06-30 | 2023-01-05 | Dupont Us Holding, Llc | Compositions and methods for microbial treatment of skin disorders |
WO2023220508A1 (en) | 2022-05-13 | 2023-11-16 | Nutrition & Biosciences USA 4, Inc. | Compositions comprising brevibacilla multifunctional fermentates and methods of use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0615745A1 (en) * | 1993-02-19 | 1994-09-21 | Howard Green | Compositions containing corneocyte proteins |
US5490980A (en) * | 1994-09-28 | 1996-02-13 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Covalent bonding of active agents to skin, hair or nails |
WO1997041215A1 (en) * | 1996-04-29 | 1997-11-06 | Novo Nordisk A/S | Non-aqueous, liquid, enzyme-containing compositions |
US5773577A (en) * | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
WO1999036570A2 (en) * | 1998-01-20 | 1999-07-22 | Pericor Science Inc | Transglutaminase linkage of agents to tissue |
-
2000
- 2000-07-24 WO PCT/US2000/020211 patent/WO2001007009A1/en active Application Filing
- 2000-07-24 EP EP00950656A patent/EP1202706A1/en not_active Withdrawn
- 2000-07-24 AU AU63730/00A patent/AU6373000A/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0615745A1 (en) * | 1993-02-19 | 1994-09-21 | Howard Green | Compositions containing corneocyte proteins |
US5773577A (en) * | 1994-03-03 | 1998-06-30 | Protein Polymer Technologies | Products comprising substrates capable of enzymatic cross-linking |
US5490980A (en) * | 1994-09-28 | 1996-02-13 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Covalent bonding of active agents to skin, hair or nails |
WO1997041215A1 (en) * | 1996-04-29 | 1997-11-06 | Novo Nordisk A/S | Non-aqueous, liquid, enzyme-containing compositions |
WO1999036570A2 (en) * | 1998-01-20 | 1999-07-22 | Pericor Science Inc | Transglutaminase linkage of agents to tissue |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6511957B1 (en) | 1993-02-19 | 2003-01-28 | Howard Green | Compositions containing corneocyte proteins |
US7390510B2 (en) | 2000-05-23 | 2008-06-24 | Sanochemia Pharmazeutika Ag | Preparation of hypericin bonded with poly-N-vinylamides |
WO2001089576A2 (en) * | 2000-05-23 | 2001-11-29 | Andreas Kubin | Preparation hypericin bonded with poly-n-vinylamides |
WO2001089576A3 (en) * | 2000-05-23 | 2002-06-06 | Andreas Kubin | Preparation hypericin bonded with poly-n-vinylamides |
WO2002007707A3 (en) * | 2000-07-21 | 2002-08-15 | Pericor Science Inc | Linkage of agents using microparticles |
WO2002007707A2 (en) * | 2000-07-21 | 2002-01-31 | Pericor Science, Inc. | Linkage of agents using microparticles |
US6713075B2 (en) | 2001-03-07 | 2004-03-30 | The Procter & Gamble Company | Topical composition comprising an aldehyde or ketone-based cosmetic bonding agent |
US6589542B2 (en) | 2001-03-07 | 2003-07-08 | The Procter & Gamble Company | Topical composition comprising a functionally alkylating cosmetic bonding agent |
US6645512B2 (en) | 2001-03-07 | 2003-11-11 | The Procter & Gamble Company | Topical composition comprising a functionally acylating cosmetic bonding agent |
US6565865B2 (en) | 2001-03-07 | 2003-05-20 | The Procter & Gamble Company | Topical composition comprising a three membered cyclic compound-based cosmetic bonding agent |
WO2002072061A2 (en) * | 2001-03-07 | 2002-09-19 | The Procter & Gamble Company | Topical composition comprising an aldehyde or ketone-based cosmetic bonding agent |
WO2002072061A3 (en) * | 2001-03-07 | 2003-05-22 | Procter & Gamble | Topical composition comprising an aldehyde or ketone-based cosmetic bonding agent |
US6607737B2 (en) | 2001-05-30 | 2003-08-19 | The Procter & Gamble Company | Topical composition comprising an activated, trans-structured cosmetic bonding agent |
US6613341B2 (en) | 2001-05-30 | 2003-09-02 | The Procter & Gamble Company | Topical composition comprising a substituted cosmetic bonding agent |
WO2003053379A1 (en) * | 2001-12-18 | 2003-07-03 | L'oreal | Cosmetic composition forming an adhesive film comprising a polymer with silicone-free skeleton including reactive functions |
FR2833486A1 (en) * | 2001-12-18 | 2003-06-20 | Oreal | Cosmetic composition especially useful for hair treatment comprises a non silicone polymer with at least two functional groups |
WO2003059299A1 (en) * | 2001-12-31 | 2003-07-24 | L'oreal | Hair treatment composition comprising an cosmetic active principle bound to biotin or a complexing agent thereof |
FR2834209A1 (en) * | 2001-12-31 | 2003-07-04 | Oreal | COSMETIC COMPOSITIONS COMPRISING A COSMETIC ACTIVE AGENT AND AN EXOGENOUS HAIR LIGAND-RECEPTOR SYSTEM AND METHOD FOR TREATING HAIR USING THE SAME |
US6812211B2 (en) | 2002-03-19 | 2004-11-02 | Michael Andrew Slivka | Method for nonsurgical treatment of the intervertebral disc and kit therefor |
US7294617B2 (en) | 2002-03-19 | 2007-11-13 | Depuy Acromed, Inc. | Method for nonsurgical treatment of the intervertebral disc and kit therefor |
EP1358867A1 (en) * | 2002-04-19 | 2003-11-05 | L'oreal | Cosmetic composition containing a biotin compound an/or a complexing agent |
FR2838640A1 (en) * | 2002-04-19 | 2003-10-24 | Oreal | A method of cosmetic treatment of hair by application of a biotin derivative and a complexing agent where either or both are bonded to a group covalently bonding to hair and either or both to a cosmetically active group |
EP1402880A1 (en) * | 2002-09-24 | 2004-03-31 | L'oreal | Cosmetic composition containing an exogenic ligand-receptor-system for binding to keratinic materials and hair treatment with this composition or it's constituting elements |
FR2844712A1 (en) * | 2002-09-24 | 2004-03-26 | Oreal | Cosmetic composition, especially for hair treatment, comprises a compound and a complexing agent capable of forming a complex with the compound |
US7220405B2 (en) | 2003-09-08 | 2007-05-22 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
US7790147B2 (en) | 2003-09-08 | 2010-09-07 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
US7285264B2 (en) | 2003-09-08 | 2007-10-23 | E.I. Du Pont De Nemours And Company | Peptide-based body surface coloring reagents |
US7807141B2 (en) | 2003-09-08 | 2010-10-05 | E.I. Du Pont De Nemours And Company | Peptide-based oral care surface reagents for personal care |
EP2374465A1 (en) | 2003-09-08 | 2011-10-12 | E. I. du Pont de Nemours and Company | Peptide-based conditioners and colorants for hair, skin and nails |
US7759460B2 (en) | 2003-09-08 | 2010-07-20 | E. I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
US7544353B2 (en) | 2003-09-08 | 2009-06-09 | E.I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
US7585495B2 (en) | 2003-09-08 | 2009-09-08 | E. I. Du Pont De Nemours And Company | Method for identifying shampoo-resistant hair-binding peptides and hair benefit agents therefrom |
US8475772B2 (en) | 2003-09-08 | 2013-07-02 | E I Du Pont De Nemours And Company | Peptide-based oral care surface reagents for personal care |
US7666397B2 (en) | 2003-09-08 | 2010-02-23 | E.I. Du Pont De Nemours And Company | Peptide-based conditioners and colorants for hair, skin, and nails |
WO2005067980A3 (en) * | 2004-01-12 | 2006-10-26 | Pointilliste Inc | Design of therapeutics and therapeutics |
WO2005067980A2 (en) * | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
EP2016934A1 (en) | 2004-09-07 | 2009-01-21 | E. I. Du Pont de Nemours and Company | Peptide-based body surface reagents for personal care |
EP2332512A1 (en) | 2005-09-28 | 2011-06-15 | E. I. du Pont de Nemours and Company | Method for enhancing effects of colorants and conditioners |
US7736633B2 (en) | 2005-09-28 | 2010-06-15 | E.I. Du Pont De Nemours And Company | Method for enhancing effects of colorants and conditioners |
EP2335780A1 (en) | 2005-09-28 | 2011-06-22 | E. I. du Pont de Nemours and Company | Method for enhancing effects of colorants and conditioners |
US7964180B2 (en) | 2005-09-28 | 2011-06-21 | E. I. Du Pont De Nemours And Company | Method for enhancing effects of colorants and conditioners |
US7906617B2 (en) | 2005-12-15 | 2011-03-15 | E. I. Du Pont De Nemours And Company | Polyethylene binding peptides and methods of use |
US7858581B2 (en) | 2005-12-15 | 2010-12-28 | E. I. Du Pont De Nemours And Company | PMMA binding peptides and methods of use |
US7709601B2 (en) | 2005-12-15 | 2010-05-04 | E. I. Du Pont De Nemours And Company | Nylon binding peptides and methods of use |
US7928076B2 (en) | 2005-12-15 | 2011-04-19 | E. I. Du Pont De Nemours And Company | Polypropylene binding peptides and methods of use |
US7632919B2 (en) | 2005-12-15 | 2009-12-15 | E.I. Du Pont De Nemours And Company | Polystyrene binding peptides and methods of use |
US7700716B2 (en) | 2005-12-15 | 2010-04-20 | E. I. Du Pont De Nemours And Company | Polytetrafluoroethylene binding peptides and methods of use |
WO2007117564A2 (en) | 2006-04-06 | 2007-10-18 | E. I. Du Pont De Nemours And Company | Clay-binding peptides and methods of use |
US8273337B2 (en) | 2007-09-14 | 2012-09-25 | Affinergy Inc. | Hair binding peptides and peptide-based hair reagents for personal care |
US8263056B2 (en) | 2007-09-14 | 2012-09-11 | E I Du Pont De Nemours And Company | Dyed-hair-binding peptides and peptide-based hair reagents for personal care |
WO2010080424A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
WO2010080418A1 (en) | 2008-12-18 | 2010-07-15 | E. I. Du Pont De Nemours And Company | Iron oxide-binding peptides |
US8354381B2 (en) | 2009-03-30 | 2013-01-15 | E I Du Pont De Nemours And Company | Peptide compositions for oral care systems |
US8481678B2 (en) | 2009-03-30 | 2013-07-09 | E I Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
WO2010114638A1 (en) | 2009-03-30 | 2010-10-07 | E. I. Du Pont De Nemours And Company | Peptide-based tooth whitening reagents |
US8388991B2 (en) | 2009-05-01 | 2013-03-05 | Chattem, Inc. | Moisturizing antimicrobial composition |
EP2516002B1 (en) * | 2009-12-21 | 2014-04-23 | Colgate-Palmolive Company | Composition for treating and/or preventing conditions caused by microorganisms using an oral light device |
US8652455B2 (en) | 2010-12-20 | 2014-02-18 | E I Du Pont De Nemours And Company | Targeted perhydrolases |
US8663616B2 (en) | 2010-12-20 | 2014-03-04 | E I Du Pont De Nemours And Company | Enzymatic peracid generation for use in oral care products |
US8815550B2 (en) | 2010-12-20 | 2014-08-26 | E I Du Pont De Nemours And Company | Targeted perhydrolases |
EP2633887A1 (en) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Novel agent combination for efficient anti-wrinkle effect |
WO2014085421A1 (en) * | 2012-11-28 | 2014-06-05 | Zarzatech, Inc. | Treatment of skin or mucosal pathology |
EP3628691A1 (en) | 2016-12-16 | 2020-04-01 | DuPont Industrial Biosciences USA, LLC | Amphiphilic polysaccharide derivatives and compositions comprising same |
WO2018112187A1 (en) | 2016-12-16 | 2018-06-21 | E. I. Du Pont De Nemours And Company | Amphiphilic polysaccharide derivatives and compositions comprising same |
US11066626B2 (en) | 2016-12-16 | 2021-07-20 | Nutrition & Biosciences USA 4, Inc. | Amphiphilic polysaccharide derivatives and compositions comprising same |
WO2019164670A1 (en) | 2018-02-26 | 2019-08-29 | Danisco Us Inc | Compositions for providing skin care benefits and methods of use |
WO2019246228A1 (en) | 2018-06-20 | 2019-12-26 | Dupont Industrial Biosciences Usa, Llc | Polysaccharide derivatives and compositions comprising same |
WO2020131711A1 (en) | 2018-12-17 | 2020-06-25 | Dupont Industrial Biosciences Usa, Llc | Polysaccharide derivatives and compositions comprising same |
WO2021155118A1 (en) | 2020-01-31 | 2021-08-05 | Dupont Us Holding, Llc | Compositions and methods for microbial treatment of skin disorders |
WO2021252575A1 (en) | 2020-06-10 | 2021-12-16 | Nutrition & Biosciences USA 4, Inc. | Poly alpha-1,6-glucan esters and compositions comprising same |
WO2021252569A1 (en) | 2020-06-10 | 2021-12-16 | Nutrition & Biosciences USA 4, Inc. | Poly alpha-1,6-glucan derivatives and compositions comprising same |
WO2021257786A1 (en) | 2020-06-18 | 2021-12-23 | Nutrition & Biosciences USA 4, Inc. | Cationic poly alpha-1,6-glucan ethers and compositions comprising same |
CN111956517A (en) * | 2020-09-20 | 2020-11-20 | 陈洁兴 | Facial cleanser and preparation method thereof |
CN111956517B (en) * | 2020-09-20 | 2022-11-25 | 苏州蜜思肤化妆品股份有限公司 | Facial cleanser and preparation method thereof |
WO2022119895A1 (en) | 2020-12-01 | 2022-06-09 | Dupont Us Holding, Llc | Methods and compositions for microbial treatment of skin disorders |
WO2023278146A1 (en) | 2021-06-30 | 2023-01-05 | Dupont Us Holding, Llc | Compositions and methods for microbial treatment of skin disorders |
WO2023220508A1 (en) | 2022-05-13 | 2023-11-16 | Nutrition & Biosciences USA 4, Inc. | Compositions comprising brevibacilla multifunctional fermentates and methods of use |
Also Published As
Publication number | Publication date |
---|---|
EP1202706A1 (en) | 2002-05-08 |
AU6373000A (en) | 2001-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6958148B1 (en) | Linkage of agents to body tissue using microparticles and transglutaminase | |
US6919076B1 (en) | Conjugates of agents and transglutaminase substrate linking molecules | |
WO2001007009A1 (en) | Lysine oxidase linkage of agents to tissue | |
EP1203141A1 (en) | Linkage of agents to tissue | |
US6267957B1 (en) | Attaching agents to tissue with transglutaminase and a transglutaminase substrate | |
KR101139979B1 (en) | Modified soy proteins in skin tightening compositions | |
KR101351467B1 (en) | Mixed-type Personal Care Product for Skin or Hair | |
JP6930990B2 (en) | Siloxane composition | |
US20030175232A1 (en) | Compositions containing enzymes stabilized with certain osmo-protectants and methods for using such compositions in personal care | |
EP3342395A2 (en) | Composition for surface modification | |
US20030157088A1 (en) | Compositions containing enzymes stabilized with inhibitors having certain binding properties and methods for using such compositions in personal care | |
EP2097059B1 (en) | Cleansing or care product | |
KR101960121B1 (en) | Personal care compositions | |
JP2019511490A (en) | Composition and preparation method | |
KR20170099656A (en) | Cosmetic compositions for moisturizing | |
JP2019529670A (en) | Silicone resin-linear copolymers and related methods | |
KR102083325B1 (en) | Cosmetics compositions for skin whitening | |
KR20170062957A (en) | Cosmetics compositions for skin whitening | |
KR20170074501A (en) | Cosmetics compositions for prevention and improvement of wrinkle | |
KR20170060429A (en) | Cosmetics compositions for skin whitening | |
JP2019537634A (en) | Silicone resin-linear copolymer and related methods | |
KR20170036276A (en) | Cosmetics compositions for skin whitening | |
KR20180003870A (en) | Cosmetic compositions for moisturizing | |
JP2001163747A (en) | Glucanase-added liquid composition for oral use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2000950656 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000950656 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10031673 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |